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INTRODUCTION 
 
 
The normal Pancreas 
 
The name Pancreas derives from the Greek roots ‘pan’ 
meaning ‘all’ and ‘creas’ meaning ‘flesh’. The pancreas, gland 
of endodermal origin, is the key regulator of protein and 
carbohydrate digestion and glucose homeostasis (Hezel AF et 
al, 2006).  The pancreas is located deep in the  abdomen, with 
the liver, intestine, and other  organs surrounding it. The 
pancreas is divided into three parts: head, body, and tail. The 
head is the thicker part of the organ and borders the duodenum, 
the common bile duct and the right renal artery and vein (Fig.1).  
The middle section, the body, and the thinnest part, the tail, of 
the organ are elongated in shape and extend to the left anterior  
to the aorta, and posterior to the stomach.   
 
 
Fig.1 Anatomy of the Pancreas 
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Functionally, the pancreas is a composite exocrine-endocrine 
gland: the prevalent exocrine portion forms up to the 84 percent 
of the pancreas volume, blood vessel and duct cells represent 
about 4 percent, and the endocrine component is only 2 
percent. The remaining (about 10 percent) is formed by 
extracellular matrix.   
 The Exocrine Pancreas is a lobulated  gland composed of 
a branching network of acinar and duct cells that produce and 
deliver digestive zymogens into the gastrointestinal tract (Slack 
JMW et al, 1995). The secretory acinar cells are grouped into  
functional units termed acini dislocated  along the duct network. 
The acinar cells are pyramidal in shape with a broad base and 
a narrow luminal face (Fig.2). In the apical cytoplasm, they 
contain zymogen granules that contain a number of digestive 
enzymes in their inactive form, including trypsinogen, 
chymotrypsinogen, ribonuclease, and amylase. In response to 
cues from the stomach and the duodenum acinar cells secrete 
zymogens into the ductal lumen. The duct system in the 
pancreas begins within the acini themselves. (Grapin-Botton A , 
2005). A narrow intercalated (intralobular) duct is deeply 
inserted into each secretory mass, the initial part of the duct 
wall being lined by low cuboidal centroacinar cells thought to 
secrete non-enzymatic components of the pancreatic juice. 
More distally these cells are replaced by taller cuboidal, and 
eventually columnar cells. The larger ducts are interlobular in 
position, and are surrounded by loose connective tissue which 
contains some nonstriated muscle fibres, and autonomic nerve 
fibres (Gray’s Anatomy, Longman 35th edition, Edhinburg, 
1975). The interlobular ducts drain directly into the duct of 
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Wirsung, the main pancreatic duct. It runs the length of the 
pancreas parallel to its long axis and joins the common bile duct 
before entering the duodenum at the papilla of Vater.  
The acini and smaller ducts are invested with a delicate, loose 
connective tissue, which becomes more extensive around the 
larger ducts. 
 
 
Fig.2  Acinar Unit 
 
 The Endocrine Pancreas regulates metabolism and 
glucose homeostasis through the secretion of hormones into 
the bloodstream. The endocrine cells are mainly grouped into 
the Langerhans islets (about 2% of the pancreas), which are 
compact spheroidal clusters embedded in to exocrine tissue 
(Fig.3). There are four major cell types that have been 
definitively identified in the islet. The β (or B) cells are the most 
numerous of the islet cell types. They synthesize, store, and 
secrete insulin, and also an insulin antagonist called amylin. 
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The α (or A) cells constitute  15  to 20 percent of the islet cells 
and they secrete glucagon. The δ (or D or A1) cells are mainly 
distributed at the islet periphery and secrete somatostatin. The 
PP (or F) cells secrete pancreatic polypeptide, and PP-rich islet 
are found particularly in the posterior part of the head of the 
pancreas. All islet cell types also express a number of products 
characteristic of neuroendocrine cells, such as neuron-specific 
enolase, tetanus toxin receptor, and the homeodomain-LIM 
protein islet-1.  
 
 
Fig.3 Endocrine Pancreas 
 
In addition to the glandular components, the pancreas has a 
rich blood supply, an extensive lymphatic drainage, and a rich 
sympathetic and parasympathetic nerve supply.  
 The main distinctive markers of the normal pancreatic 
cells are the Cytoskeleton Intermediate Filament (IF) proteins 
(Bouwens L, 1998; Schussler MH et al, 1992). Keratins (CK), 
the major IF proteins of epithelial cells, comprise a family of 
nearly 20 different polypeptides and are classified into two 
subfamilies according to the Moll’s catalogue (Moll R at al, 
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1982): type I CK (keratins 9-20) are acidic and have a low 
molecular weight; type II CK (keratins 1-8) are neutral to basic. 
Keratin filaments contain at least one member from the type I 
subfamily and one member from the type II subfamily (Chu PG 
et al, 2002), and the different pairs of keratins are expressed in 
a tissue-specific manner. This finding means that a given 
specific epithelial cell can be characterized by the specific 
pattern of its keratin components.  
Keratin immunohistochemistry is a very useful tool for 
identifying different cell types in the pancreas. The normal 
pancreas is composed of simple, non-stratified epithelia and so 
it expresses the typical combination of keratin 8 and 18, and 
keratin 7 and 19. The acinar cells express CK 8 and 18, while 
CK 7 and 19 are not express in this type of cells. Centroacinar 
cells and ductal cells share a similar CK pattern: CK 7, 8, 18, 
and 19 are in fact consistently and homogeneous expressed.  
Keratin staining is more intense in exocrine than in endocrine 
cells, with the highest levels of staining in the larger ducts. In 
the endocrine pancreas, islet cells constantly express only CK8 
and CK18. The main distinctive cytokeratin proteins of 
pancreatic cells are listed in Table N.1 
 
Table N.1: Expression of CKs in Normal Pancreas 
Cell type CK 8,18 CK 7,19 
Ductal + + 
Centroacinar + + 
Acinar + - 
Endocrine + - 
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Pancreatic Cancer 
 
 
Classification of Pancreatic Cancer 
 
The Pancreas is a particularly important organ from the point of 
view of human medicine because it suffers from two important 
disease: diabetes mellitus and pancreatic cancer.  
 ‘Pancreatic cancer’ is a broad term to describe as many as 20 
different types of tumor that can occur in the pancreas. 
Pancreatic cancer is categorised as being either endocrine or 
non-endocrine (exocrine).  The phenotypic classification of 
pancreatic neoplasms is based on their cellular lineage, thus 
tumor with a ductal, acinar, and endocrine phenotype can be 
distinguished.  
 Endocrine tumors represent only about one percent of all 
pancreatic cancers. They affect the hormone-producing cells of 
the pancreas and can have dramatic effects on the amounts of 
hormones produced. These type of tumors regard, for example,  
Insulinomas, which can cause excessive insulin production 
resulting in low blood sugar, and Glucagonomas, which may 
cause excessive glucagons production, resulting in a distinctive 
skin rash.  
 Exocrine tumors make up the majority of pancreatic 
cancer (more than 90 percent). Most pancreatic neoplasms 
show a ductal line of differentiation and therefore classified as 
ductal adenocarcinomas. The fine structure of PDAC cells 
resembles that of the pancreatic duct cells. The luminal surface 
Introduction 
  7
of the cells shows microvilli; the apical cytoplasm contains 
mucin granules, and the basal part of the cells contains a round 
nucleus with a small distinct nucleolus. The morphologic 
features of this tumor include infiltrating duct-like and tubular 
structures embedded in a high desmoplastic stroma. The tumor 
cells, like the ductal cells of the normal pancreas, produce 
mucins. Other duct cells markers that are typically found in 
PDAC are the cytokeratin 7, 8, 18, and 19, CA 19.9, and CEA.  
Pancreatic Ductal Adenocarcinoma (PDAC) is the most 
common form of pancreatic cancer comprising  85 to 90 percent 
of all pancreatic tumours. Less common tumors with a ductal 
phenotype are the variants of ductal  adenocarcinoma, 
intraductal papillary mucinous neoplasm (including colloid 
carcinoma), mucinous cystic neoplasm, medullary carcinoma, 
and other rare tumors (Kloppel G et al, 2004).   
  
 
Epidemiology 
 
Incidence and mortality 
PDAC is characteristically a tumour of elderly individuals: 
approximately 80 per cent of cases occurs in patients between 
the ages 60 to 80; patients below the age of 40 are rar (Lüttges 
J, et al 2004). 
PDAC ranks eight in a worldwide ranking of cancer deaths, 
(Lowenfels AB et al, 2006) while with respect to incidence, it 
ranks 13th being then considered a relatively rare tumor. PDAC 
is one of the most lethal human cancers and continues to be a 
major unsolved health problem at the start of the 21st century 
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(Li D et al, 2004). The poor 5-year survival rate (5%) and the 
median survival of less than 6 months are  largely the result of 
PDAC’s silent nature and of a late diagnosis (Sakorafas et al, 
2000). The vast majority of patients do not exhibit specific 
symptoms until the disease is advanced. Specific symptoms 
usually only develop after invasion or obstruction of nearby 
structures. As most pancreatic cancers arise in the head of the 
pancreas, obstruction of the biliary tree resulting in jaundice is 
the hallmark presentation (Lillemoe KD et al, 2000) .  
Moreover close to 100% of patients with pancreatic cancer 
develop metastases at the time of diagnosis, as a 
consequence, only 20% of pancreatic cancer patients are 
eligible for radical surgical resection, which currently remains 
the only potentially curative therapy.  
Conventional therapeutic cancer strategies such as 
chemotherapy and radiotherapy have failed to significantly 
improve the prognosis of advanced pancreatic cancer, due to 
its unusual resistance  to chemotherapy and radiation therapy. 
These information indicate that current interventions to prevent, 
diagnose, and cure the disease are still far from being 
satisfactory.  
 
Risk factors 
Large studies and country specific differences in cancer 
frequency, have showed that environmental factors are the 
most important cause of most type of cancer, including 
pancreatic cancer.  
Data from early epidemiologic studies of pancreatic cancer 
(Wynder EL et al, 1973) showed that carcinogens derived from 
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tobacco, occupational or other environmental sources might 
enter the bile and then cause pancreatic cancer by reflux 
through the pancreatic duct. This hypothesis has never been 
disproved and could explain the excess of pancreatic cancer 
known to occur in the head of the pancreas. Current data 
confirm only three types of risk  factors linked with pancreatic 
cancer: cigarette smoking, chronic pancreatitis and diabetes (Li 
D et al, 2004).  
 About 30 percent of cases of pancreatic cancer are 
attributable to smoking (de Braud F et al, 2004). Cigarette 
smokers develop this disease 2-3 times more than non-
smokers, while exposure to environmental smoking (passive 
smoking) cause a non-significant increase in the risk of 
pancreatic cancer. The harmful effect of smoking is mainly 
related to mutagens present in the metabolites of tobacco 
smoke (Lowenfels AB et al, 2006).  Recent findings from large-
scale population-based case-control studies support the 
hypothesis that individuals who have deficient detoxifying 
and/or DNA repair systems are at  increase risk of pancreatic 
cancer.  
  In Western countries the most common cause of chronic 
pancreatitis is heavy alcohol consumption. Cohort studies have 
confirmed a link between pancreatitis and pancreatic cancer.  
Another cause of chronic pancreatitis is hereditary pancreatitis. 
This is a rare inherited autosomal disease with an onset in 
childhood or early adulthood. Patients with hereditary 
pancreatitis experience a 53-fold increased incidence of 
pancreatic cancer (Bardeesy N et al, 2002). The link between 
chronic pancreatitis and pancreatic cancer has not fully 
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investigated at the molecular level. Increased cell turnover, 
defective DNA repair, loss of p16 expression along with K-ras 
gene mutations, have been found in nearly all pancreatic 
cancer and also in chronic pancreatitis samples. 
 Diabetes  is a disorder found in 5-10 % of the general 
population. A recent study found  a modest relationship 
between longstanding diabetes of >5 years and pancreatic 
cancer, while the higher risk was found for less than 5 year 
diabetic patients. These studies are biased since diabetes can 
be an early manifestation of pancreatic cancer.  
 
 
PDCA Morphological Characteristic and 
Progression  Model 
 
Pancreatic desmoplastic reaction 
The importance of stromal interactions with epithelial cells is 
well established in embryonic development and tumorigenesis. 
The concept of a link between stromal and adjacent epithelial 
cells was introduced more that 20 years ago (Cunha GR, et al, 
1980). The interaction is mediated by soluble paracrine signals 
and extracellular matrix (ECM) components secreted from 
developing  mesenchimal cells that  induce  adjacent epithelial 
cells to proliferate rapidly (Bissel MJ at al, 2001). Therefore 
tissue differentiation appears to be a coordinate process 
involving both epithelial and mesenchimal cells . Differentiated 
stromal cells generally express lower quantities of growth 
factors, and differentiated epithelia express cytokines for the 
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maintenance of stromal differentiation, suggesting that a new 
balance of mesenchimal-epithelial crosstalk is reached during 
maturation. (Bhowmick NA et al. 2004). This fine tuning of 
epithelial/stromal interactions is deeply disturbed during 
tumorigenesis so that tumor microenvironment may influence 
tumor characteristics such as tumor differentiation, growth rate 
and drug sensitivity. On the other hand, tumor cells can 
regulate the development of the tumor stroma by aberrant 
expression of growth factors or induction of growth factor 
receptors in stroma compartment (Micke P and  Ostman A, 
2004).  
 In many human tumors the stroma microenvironment is 
both morphologically and biologically  different from the 
corresponding normal stroma. This “reactive stroma” is 
characterized by the presence of fibroblasts with an “activated” 
phenotype embedded in a  modified ECM with an increased 
microvessel density and  presence of inflammatory cells.  These 
modified fibroblasts, often termed myofibroblasts, reactive 
stroma or cancer-associated fibroblasts (CAFs), are considered 
to play a central role in the complex process of tumor-stroma 
interaction and consequently tumorigenesis (Desmouliere A et 
al, 2004).  
Extreme representations of the desmoplastic reaction is 
particularly evident in certain tumor types, such as scirrhous 
breast cancer, biliary and pancreatic carcinomas. A pathologic 
characteristic of pancreatic cancer is, in fact, a pronounced 
desmoplastic (stromal) reaction around tumour tissue (Luttges J 
et al, Med Klin 2004). Neoplasms like pancreatic carcinoma are 
in fact  typically composed of infiltrating ductlike structures 
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surrounded by a dense fibrous or desmoplastic stroma. Rather 
unique to ductal adenocarcinoma is the consistently low ratio of 
the infiltrating adenocarcinoma cells relative to the abundant 
desmoplastic stromal environment, with pancreatic cancer cells 
represent on average  25% of the cells in the tumor mass (Apte 
MV et al, Pancreas 2004). Pancreatic desmoplastic reaction  is 
composed of connective tissue (predominantly collagen type I 
and other glycoproteins) and new blood vessels and is 
associated with proliferation of fibroblastic cells. The reactive 
stroma itself contains a variety of cells including proliferating 
fibroblasts, small endothelial-lined vessels, inflammatory cells 
and residual parenchymal components of the invaded organ. It 
is now clear that host stromal reaction is far from being a 
passive actor in the neoplastic process and may strongly 
influence the behaviour of  neoplastic cells (Iacobuzio-Donahue 
CA, Ryu B, Hruban RH, Kern SE, 2002). Cytokines, growth 
factors and angiogenic factors released by these cells may 
positively influence tumor growth, metastatic capabilities and 
contribute to drug resistance (Kopfstein L, Christofori G, 2006).  
 
Introduction 
  13
 
Fig.4  Crosstalk between tumour cells and their activated stroma 
 
Despite the importance of tumor-stroma interaction in 
cancer progression, the underlying molecular mechanisms have 
not been yet well characterized. Several molecules have been 
identified to participate in tumor-stroma interaction including 
Hepatocyte growth factor (HGF), Interleukin-8 (IL-8) 
SPARC/osteonectin, Transforming Growth Factor Beta, several 
Matrix Metalloproteinases (MMPs) and reactive oxygen species 
(COX) (Müerköster S, et al 2004).  Moreover, different gene 
expression profiles have been generated by experiments done 
using co-cultures of pancreatic cancer cells and stromal 
fibroblasts (Fig.4). These experiments  confirmed the existence 
of and active cross-talk between cancer and normal cells (Sato 
N, Maehara N and Goggins M, 2004). The possibility to identify 
the molecular pathways involved in this cross-talk may allow us 
to provide new targets susceptible of therapeutic intervention  
(Corsini C et al, 2003). In fact, stromal therapy is emerging as 
an alternative approach to cancer prevention and therapy. 
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Irradiated fibroblasts can cause activation of c-Met oncogene in 
pancreatic cancer cells enhancing its invasiveness while the 
administration of a specific antagonist of c-Met may block this 
effect (Ohuchida K, et al, 2004). A phase-I dose-escalation trial 
recently published (Scott AM, et al , 2003) utilizing humanised 
monoclonal antibodies (sibrotuzumab) against the fibroblast 
activating protein (FAP) showed promising results in controlling 
colorectal cancer.  
 
 
The “Adenoma-Carcinoma Sequence”  
 Invasive PDAC is an almost uniformly fatal disease also 
because of lack of effective screening test for early pancreatic 
cancer. A better understanding of the pathogenesis of 
pancreatic cancer and more effective screening techniques are 
required to improve current survival rates. To this purpose it is 
important to know the characteristics of pre-cancerous lesions 
of PDC because they provide a unique opportunity to 
understand the early events in the development of an infiltrating 
carcinoma, and a better understanding of these events, in turn, 
may lead to the development of novel diagnostic techniques to 
detect this cancers in early stages.  (Brat DJ et al, 1998).  
The first evidence that there may be a distinctive precursor 
lesion to infiltrating adenocarcinoma of the pancreas came from 
morphological studies. In 1976 Cubilla and Fitzgerald identified 
histologically distinct proliferative non-invasive lesions in the 
pancreatic ducts and ductules adjacent to infiltrating 
adenocarcinoma of the pancreas. They called these duct lesion 
“hyperplasia” and showed that they were more commonly found  
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in tissues adjacent to cancer than in fully healthy organ. Thus, 
morphological observation provided the first critical step in the 
recognition that intraductal proliferations in the pancreas could 
represent the morphologic precursors to invasive ductal cancer.  
These precursor lesions were later termed pancreatic 
intraepithelial neoplasia (PanIN),( Hruban RH et al, 2004; 
Hruban RH et al, 2000) by the National Cancer Institute-
sponsored Pancreatic Think Tank, and they were graded from 
stage I to stage III (PanIN-1A to PanIN-3) (Fig.5).  PanIN-1A are 
characterized by the transition from cuboidal to tall columnar 
cells with still basally located non-atypical nuclei. PanIN-1B is 
cytologically indistinguishable from PanIN-1A, but show a 
distinct papillary or pseudo-stratified architecture. PanIN-2 
lesions manifest architecturally as flat or papillary lesions but 
they show a higher degree of nuclear atypia. Finally  the PanIN-
3 lesions (also known as “carcinoma in situ”) bear a cytologic 
resemblance to infiltrating carcinoma despite the fact they are 
still contained within the ductal basal lamina. The cells are 
characterized by profound nuclear atypia, prominent nucleoli 
and mitotic activity (Baumgard M et al, 2005; Takaori K et al, 
2004; Hruban RH et al, 2000).   
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Fig.5   Histologic Progression Model for Pancreatic Cancer. 
 
These morphological observations were, however, static, and 
there was not universally agreement upon whether these 
pancreatic duct lesions could represented the true intraductal 
phase of an invasive cancer (Luttges J et al, 1999). Molecular 
analyses have provided strong evidences that pancreatic 
intraductal lesions are indeed the precursors of infiltrating 
adenocarcinomas. 
Most genetic abnormalities commonly identified in infiltrating 
ductal adenocarcinoma, such as k-ras, p16, p53, and DPC4, 
have also been found in PanIN duct lesions. Moreover 
molecular studies have helped to define the time axis of the 
progression of the PanIN lesions to invasive PDAC showing 
that the genetic mutations that take place in the precursors 
lesions appear to occur in a temporal sequence rather than a 
random fashion (Vimalachandran D et al, 2004), so that relative 
frequencies of a given molecular abnormality increases with the 
increasing grade of the PanINs with an overall cumulative 
effect. These findings shape a progression model  similar to 
that described for colorectal cancer. K-ras mutations are the 
first molecular abnormality detectable in PanIN – Carcinoma 
Normal PanIN-1A PanIN-1B PanIN-2 PanIN-3 Infiltrating 
carcinoma 
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sequence being also found in the adjacent normal-appearing  
pancreatic ducts (Luttges J et al,  1999). K-ras mutation rate 
increases up to virtually all PanIN-3 lesions and  infiltrating 
adenocarcinomas, much to be considered a sort of  “signature”  
of pancreatic cancer.  Telomerase activity is significantly higher 
in invasive lesions compare to normal adjacent structures, 
nevertheless it is peculiar that this high activity is preceded by a 
shortage of telomere that have been documented in all types of 
pre-invasive lesions. (Heek NT et al, 2002). Considering the 
fundamental role exerted by telomeres in normal chromosomal 
separation this finding may predispose these non-invasive 
ductal lesions to accumulate progressive chromosomal 
abnormalities and to develop toward the stage of invasive 
carcinoma. 
 The second step include p16, p53, DPC4, and BRCA2 
inactivation. Loss of p16 INK4A is found to be the next hit, 
occurring slightly later than K-ras (Fig.6).  Allelic loss has been 
detected in PanIN-2, and inactivation has been found up to 
100% in invasive cancer (Moskaluk CA et al, 1997). The p53 
gene inactivation is a later event, usually occurring in PanIN-3 
lesion and in near 75% of infiltrating PDAC. Inactivation of 
DPC4 and BRCA2 genes appear to be a late event in genetic 
progression of pancreatic cancer, occurring in histologically 
high- grade lesions and infiltrating PDAC. The validity of this 
histologic-genetic progression model is also been confirmed by 
a study of the proliferative rate of the epithelial cells in the 
successive grades of PanINs (Klein WM et al, 2002). The Ki-67 
expression  was used as a proliferative marker and correlated 
with the PanIN lesions histology.  Data from this  study showed 
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that the Ki-67 labelling rate parallel an increasing grade of 
dysplasia, leading to a better understanding of the pancreatic 
progression model.     
 
 
 
 
 
 
 
Fig.6  Histologic-Genetic Progression Model for Pancreatic Cancer. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Normal PanIN-1A PanIN-1B PanIN-2 PanIN-3 Infiltrating 
carcinoma 
K-ras 
Shortened 
telomeres
p16 
p53;  DPC4 
BRCA2 
Low proliferative rate High proliferative rate 
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PDCA Molecular Genetic 
 
A careful molecular analysis of infiltrating PDAC revealed that 
this carcinoma, like other cancers, showed  a characteristic 
pattern of genetic lesions comprising activation of oncogene 
and inactivation of tumor suppressor genes (Fig.7). PDAC it is 
characterized by a well-established molecular fingerprint 
comprising activation of K-ras oncogene (90%) of cases and 
inactivation of tumor suppressor genes like p16, p53, and DPC4  
(90%, 60%, and of 50% cases respectively).  
 
 
 
 
 
Fig.7 Major pathways in the development of pancreatic 
adenocarcinoma.   
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Oncogenes in PDAC 
Oncogenes are defined as dominant genes that can induce or 
maintain cellular transformation. They are often related to normal 
cellular genes, called proto-oncogenes, which have critical 
functions in cellular growth or differentiation. Oncogenes may be 
activated in various ways, by point mutations, amplification and 
chromosomal translocation. Most oncogenes code for proteins 
that are thought to be major players in the control of cell growth.  
   
 
KRAS  
The mammalian ras gene family consist of three members: H-
ras, K-ras, and N-ras, were originally identified in the mild-1960s 
as the transforming elements of the Harvey and Kirsten strains of 
rat sarcoma viruses. H-ras and K-Ras oncoproteins were 
identified as viral (v-Ras) oncoproteins of Harvey and Kirsten 
murine sarcoma viruses, and were found to be capable of cellular 
transformation. The N-Ras oncoprotein was identified in a 
neuroblastoma cell line (Macaluso M et al, 2002).   H-ras,  K-Ras, 
and  N-Ras genes are located in different chromosomes,  
11p15.5, 12p12.1, and 1p13, respectively. RAS-family proteins 
are low-molecular-weight guaninenucleotide-binding proteins and 
the three ras genes encode four highly related p21kDa GTPases 
of 188 (K-RasB) or 189 (K-RasA, H-Ras, and N-Ras) amino 
acids in length. The A and B forms of K-Ras are generated by an 
alternative splicing of the fourth exon of this gene, and the 
abundance of the K-RasB transcripts is higher in comparison of 
that of K-RasA transcripts. Ras is ubiquitously expressed 
although mRNA analysis suggests different tissue expression 
Introduction 
  21
levels. H-Ras is highly expressed in the skin and in skeletal 
muscles, K-Ras is mostly expressed in the colon and the thymus, 
and N-Ras in male germinal tissue and the thymus. Ras proteins 
are essential components of receptor-mediated signal 
transduction pathways that control cell proliferation and 
differentiation (Bar-Sagi D, 2001).  Ras is synthesized as a 
biologically inactive cytosolic propeptide (Pro-Ras) and is 
localized to the inner surface of the plasma membranes only after 
it has undergone a series of closely linked posttranslational 
modifications at the C-terminus, thereby increasing its 
hydrophobicity and facilitating its association with the plasma 
membrane where they can interact with their upstream activators 
and downstream targets. The association of Ras proteins with 
the plasma membrane involves a series of posttranslational 
modifications in their C termini. These modifications increase the 
hydrophobicity of the C terminal region of the proteins allowing its 
inner in plasma membrane (Hancock JF, 2003; Prior IA et al, J 
2001  ) . All the Ras proteins contain in fact a terminal CAAX box 
in the 186-189 position. In this box, the “C” represents cysteine, 
“A” represents an aliphatic amino acid (leucine, serine, or valine) 
and “X” is metionine, serine, leucine, or glutamine.  The first step 
in this process is the farnesylation of the cysteine in the CAAX 
box at the C-terminal end. Subsequently, the AAX amino acids 
are cleaved off by Ras-converting enzyme I, and then the 
farnesylated cysteine is carboxymethylated by isoprenylcysteine 
carboxyl methyltransferase.  Upon palmitoylation (HRas, N-Ras, 
and KRas-4A) or through the presence of a polybasic domain 
(KRas-4B), the protein is anchored in the cell membrane (Chiu 
ViK et al, 2002) (Fig.8).  
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Fig.8 Posttranslational modification of Ras proteins (from Hancock 
JF,2003). 
 
 
  Ras proteins function  is regulated by cycling between 
inactive GDP-bound state and active GTP-bound forms, and this 
ability makes them ideal signal transducers (Joneson T, 1997).
 In quiescent cells, RAS exists predominantly in the GDP-bound 
state. Ras proteins are activated transiently in response to a 
diverse array of extracellular signals such as growth factors, 
cytokines, hormones and neurotransmitters that stimulate cell 
surface receptors, and integrins.   The best-studied activation 
mechanism involves the assembly of complexes of activated, 
autophosphorylated growth-factor receptor tyrosine kinases with 
the GEF SOS through the adaptor protein GRB2, and possibly 
SHC, resulting in the recruitment of SOS to the plasma 
membrane, where RAS is located (Downward J  , 2003).  
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Fig.9 Signalling upstream of RAS (from Downward J, 2002). 
 
In the GDP-bound form they are inactive, but upon replacement 
of bound GDP with fresh GTP they undergo an activating 
conformational change (Fig.9). The intrinsic GDP/GTP exchange 
activity of Ras is very low and hence increase in GDP/GTP 
nucleotide exchange involves interaction between Ras and the 
regulatory protein guanine exchange factors (GEFs) (Campbell 
SL et al, 1998).  Once activated, Ras is able to interact with and 
activate effector proteins, which in turn stimulates signalling 
cascades that induce a variety of cellular responses designed to 
prolong cell survival and promote cell proliferation. Ras-GTP 
exist for only a short time because it is subsequently inactivated 
by a class of proteins known GTP-ase-activating proteins 
(GAPs), which enhance the Ras intrinsic low GTPase activity 
(Singh A et al, 2005).  
  GTP-bound RAS is able to bind and activate several 
families of effector proteins, resulting in stimulation of their 
catalytic activity. The main effectors are the RAF–MEK–
ERK/MAPK, Phosphatidylinositol 3-kinase (PI3K) pathways, 
RAL, and Phospholipase Cε (PLCε)  (Shields JM et al, 2000). 
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 The first mammalian effector of RAS to be characterized is the 
protein serine/threonine kinase RAF. GTP-bound RAS binds to, 
and  activates the three closely related RAF proteins, c-RAF1, 
BRAF, and ARAF. This interaction cause RAF to be relocated to 
the plasma membrane, which is crucial for its activation.  
Downstream of this, activated  RAF, phosphorylates  and actives 
activates the dual-specificity mitogen- tyrosine/threonine kinase 
MEK (MEK1 and MEK2). Active MEK then phosphorylates 
ERK/MAPK, which translocates to the nucleus and activates a 
variety of transcription factors. As a result of stimulating these 
transcriptional regulators, protein such as D-type cyclins are 
expressed. So RAF activation can promote cell-cycle 
progression, at least in conjunction with other signals (Fig.10). 
 RAS can interact directly binds and activates the catalytic 
subunit of Phosphatidylinositol 3-kinase (PI3K), a lipid kinase that 
generates phosphatidylinositol 3,4,5- trisphosphate 
(PtdIns(3,4,5)P3) second messengers, which bind to a large 
number of proteins through the plecktrin homology and other 
domains. In this way PI3K controls the activity of a large number 
of downstream enzymes such as phosphoinositide-dependent 
kinase-1 (PDK1) and AKT/protein kinase B (AKT/PKB) kinases . 
AKT/PKB has a strong anti-apoptotic function by phosphorylating 
various targets and is an important part of the survival signal that 
is generated by RAS. In addiction, PI3K activation leads to 
stimulation of RAC, a RHO family protein that is involved in the 
regulation not only of the actin cytoskeleton, but also of 
transcription-factor pathway-for example nuclear factor kB (NF-
kB).  
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 RALGDS proteins are guanine nucleotide exchange factors 
(GEFs) for RAL, a RAS-related protein. Through these proteins, 
RAS is able to stimulate RAL, resulting in control of downstream 
effectors such as the inhibition of Forkhead transcription factors 
of the FoxO family. These have been implicated in promoting 
cell-cycle arrest through KIP1 (p27), and apoptosis.  
 Phospholipase Cε (PLCε) is another RAS effector that as been 
reported recently. It catalyses the hydrolysis of 
phosphatidylinositol-4,5-bisphosphate to diacylglycerol and 
inositol trisphosphate, resulting in protein kinase C (PKC) 
activation and calcium mobilization from intracellular stores.  
 
 
Fig.10 Signalling downstream of RAS (from Downward J, 2002). 
 
  Activating point mutations of ras genes is the most 
commonly event detected in human tumors,   occurring  in 
approximately 20% of all cancers. With regard to the three ras 
genes, mutation of K-RAS is the most commonly found (about 
85% of total), whereas N-RAS mutations are encountered less 
often (about 15%) and H-RAS mutations rarely (less than 1%) 
(Downward J, 2003). KRAS mutations are one of the most 
Introduction 
  26
common mutational events in the carcinogenesis of human 
malignancies. It has been estimated that as many as 75-90% of 
pancreatic cancer, 50% of colorectal carcinoma, and 25% of non-
lymphocytic leukemias have ras gene mutations. having 
mutations in human cancer samples. RAS mutations are somatic 
rather than in the germ-line, and consist of single base-pair 
substitutions which lead to the change of one amino acid in the 
protein. The hotspots mutations are located at codon 12 , codon 
13, and, with a low frequency, at codon 61. All these mutations 
involve amino acid substitution  near the bound nucleotide 
making RAS protein insensitive to GAPs. This results in a RAS 
mutant protein  persistently  activated in the absence  of 
extracellular signalling . Mutations in codon 12 or in codon 13 
reduces the intrinsic GTPase activity of the ras gene product, but 
mutation in codon 61 results in ras protein with no catalytic 
activity at all. The reason for the specificity of these mutations to 
codon 12 is not entirely clear and may be due to etiologic agents 
binding preferentially to this codon and to poor repair of adducts 
formed at this codon compared with DNA damage occurring at 
other codons. However, a closer look at the mutation spectrum of 
K-ras suggest that the explanation may be more complex (Howe 
JR et al, 1997).  
  The highest incidence of KRAS mutations has been found 
in PDAC, with a range of K-ras mutations from  60% to 100% of 
cases. Activating KRAS mutations are the first genetic changes 
that are detected in the pancreatic cancer progression series, 
occurring occasionally in histologically normal pancreas and in 
about 30% of lesion that show the earliest stages of histological 
disturbance (Bardeesy N et al, 2002). KRAS mutations increase 
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in frequency with disease progression, and are found in nearly all 
100% PDAC. The KRAS mutations in PDAC are almost 
exclusively at K-ras codons 12 and 13 and , to a lesser extent, at 
codon 59,  61, and 63 (Deramaudt T et al, 2005). 
K-RAS point mutations have been also described in the majority 
of pancreatic ductal adenocarcinoma cancer cell lines that are 
commonly used in laboratory-based investigation and xenografts 
models in nude mice.  
KRAS mutations are an initiating step in PDAC pathogenesis, 
and detailed pathological studies have demonstrated that KRAS 
mutations are one of the early genetic events seen in human 
PanIN progression.  KRAS plays an essential role in 
maintenance of advanced PDAC, as suggested by dominant-
negative mutant study .  
The high frequency of KRAS mutations has led to speculation 
regarding its application as a diagnostic tumor marker, as well as 
a prognostic indicator. Since now, however only two studies 
found that KRAS mutations offer prognostic information post 
resection. In these studies patients with KRAS mutation exhibited 
a shorter survival time and recurrence after surgery than those 
with the wild-type gene (Castells A et al, 1999; Niedergethmann 
M et al, 2002). However, the subtype or number of KRAS 
mutations may offer greater information regarding survival. In the 
largest number of pancreatic cancer specimens so far studied, 
GaT,cGT and GcT mutations demonstrated shorter median 
survival times when compared with other mutations (Kawesha A 
et al, 2000).  
There have been attempts to inhibit KRAS in PDAC, mainly 
through inhibition of post-translational modifications. Despite 
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promise in vitro and in PDAC xenografts, farnesyltransferase 
inhibitors (FTIs) have not been clinically effective. Among the 
explanations for the clinical failure of FTIs, compensatory 
geranyltransferase activity preserving RAS function has been 
suggested. 
 
 
 
 
Tumor Suppressor Genes in PDAC 
The tumor suppressor genes contribute to tumorigenesis through 
their loss of function. When only one copy of tumor suppressor 
gene harbours an inactivating mutation, the remaining wild-type 
copy may be adequate to maintain the tumor suppressor 
function. Therefore, mutations in tumor suppressor genes 
generally involve both copies of the gene and the second 
inactivating mutation is most often the loss of a chromosome 
region containing the gene, also called allelic loss or loss of 
heterozygosity (LOH).  Proteins encoded by tumor suppression 
genes have important role in regulating cellular differentiation and 
proliferation. 
 
 
CDKN2A 
The INK4a/Arf locus, situated on chromosome 9p21, is among 
the most frequent sites of genetic loss in human cancer. Deletion 
of this locus is seen with high frequency in a variety of 
malignancies, including melanoma, glioblastoma, and pancreatic 
adenocarcinoma (Sharpless NE, 2005). The INK4a/Arf locus 
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encodes two tumor suppressors  P16 ink4a and p14ARF, whose 
expression enhances the growth-suppressive functions of the 
retinoblastoma protein (Rb) and the P53 transcription factor, 
respectively. The genetic organization of the INK4a/Arf locus is 
unusual because the two protein products are encoded in part by 
common nucleotide sequences that are read in alternative 
frames (Fig.11). This open reading frame has its own promoter 
and first exon (exon 1β for p14ARF and exon 1α for P16 ink4a), but 
splices into the common second and third exons. Consequently, 
the two proteins are encoded in alternative reading frames, and 
therefore are not isoforms and have no amino acid homology. 
While the encoding of open reading frames in overlapping 
stretches of the genome is common in viruses and bacterial, 
such genomic structure is practically unique in the mammalian 
genome. 
 
 
 
 
 
Fig.11. The INK4a/Arf locus (from Sharpless NE, 2005). 
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The P16Ink4a and p14ARF tumor suppressor proteins function in 
distinct anti-cancer pathways: P16 ink4a regulates Rb and p14ARF 
regulates p53.  
  p16INK4a is an inhibitor of the cyclin-dependent kinases, 
CDK4 and CDK6, which promote proliferation. The binding of the 
p16INK4a protein to CDK4 and CDK6 induces an allosteric change 
that abrogates the binding of these kinases to D-type cyclins, 
inhibiting CDK4/6-mediated phosphorylation of retinoblastoma 
(Rb) family members. Thus, expression of p16INK4a maintains 
Rb-family proteins in a hypophosphorylated state, which 
promotes binding E2F to effect a G1 cell-cycle arrest (Kim WJ et 
al, 2006) (Fig.12).  
 
 
Fig.12 The P16Ink4a function in cell cycle arrest (from Chin L, 1998). 
 
  p14ARF stabilizes p53 by inhibiting its Mdm2-dependent 
proteolysis. ARF can interfere with all of the  known functions of 
Mdm2, including its ability to block p53 transcription; to 
ubiquinate p53; and to enforce p53 transport into the cytoplasm, 
where it is degraded in proteasomes (Sherr CJ, 2000) (Fig.13).  
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Fig.13 The P14ARF function in cell cycle arrest (from Chin L, 1998). 
 
The critical property that distinguish p16INK4a seems to be its 
capacity to be transcriptionally upregulated in response to 
senescence stress.  These evidences were motivated by the 
seminal observation of Sherr and colleagues (Zindy et al., 1997), 
that the expression of p16INK4a increases markedly with aging in 
many tissues of rodents and humans. Moreover, as aging is 
characterized in part by a reduced ability of reservoirs of self-
renewing tissue stem cells to regenerate lost or damaged cells, 
this observation has suggested the possibility that an age-
induced increase in p16INK4a expression contributes to the decline 
of replicative potential of certain self-renewing compartments with 
aging. 
p16INK4a age-dependent antiproliferative effects has been 
documented in true stem cells (HSCs and NSCs) as well as 
unipotent progenitors (pancreatic β cells). However, β cells from 
old p16INK4a knockout mice demonstrated less regenerative 
capacity than those of young wild-type mice, meaning that 
p16INK4a loss did not completely abrogate the effects of aging. 
Thus,  p16INK4a-independent aging may occur in the 
p14ARF
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compartments of the organ studied (bone marrow, brain, or 
endocrine pancreas). Recent studies point out a role for p16INK4a 
in preventing centrosome dysfunction and genomic instability in 
primary cells. Loss of p16INK4a generates supernumerary 
centrosomes in human diploid epithelial cells with the 
consequence production of aneuploid daughter cells as a result 
of unequal segregation of the genomic material during mitosis 
(McDermott KM et al, 2006; Jacobs JJ and de Lange T, 2005).  
p14ARF was initially found to be a mediator of p53-dependent 
apoptosis in response to the cell cycle dysregulation associated 
with Rb deficiency, suggesting ARF linked oncogenic stress to 
p53. Several additional form of oncogenic stress including 
expression of v-abl, c-myc, or loss of RB have been 
demonstrated to induce ARF and thereby stabilize p53. Of 
interest, this response to oncogenic expression depends on 
cellular context, as RAS potently induces ARF in murine, but not 
human, cells. In murine embryo fibroblasts, the expression of 
p19ARF correlates with the onset of senescence, in contrast 
p14ARF does not appear to play a major role in the replicative 
senescence of normal human cells, a phenotype mediated by 
p16INK4a and/or p53. 
 As cancers frequently harbour homozygous deletions of the 
INK4a/ARF/ locus, several studies have been performed to 
highlight the relative importance of the two INK4a/ARF/ locus 
encoded  proteins in tumors. 
In murine cancers, in vivo experiments indicate that p19ARF, the 
mouse homolog of p14ARF, play an important protective role in 
oncogenic transformation and tumorigenesis (Kamijo et al, 1997). 
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In human cancers, epidemiological and experimental data 
(Voorhoeve PM and Agami R, 2003) implicate p16INK4a as the 
more important tumor suppressor gene product in the human 
INK4A locus. Specific somatic loss of p16INK4a, through point 
mutation or small deletion, has been reported in thousands of 
human cancers (Forbes et al., 2006). p16INK4a was one of the first 
genes noted to be silenced epigenetically in human cancers, and 
silencing through promoter methylation is well described at high 
frequency in numerous types of human cancers (Esteller et al, 
2001). Somatic ARF-specific mutations and promoter methylation 
have been reported in studies of colon cancer (Burri et al, 2001; 
Esteller et al, 2001), but such specific targeting events appear 
less common in human cancer than those affecting only p16INK4a 
(Kim WJ et al, 2006).  
The role of p16INK4a in tumorigenesis is important particularly in 
melanoma and pancreatic carcinoma. The findings of germline 
p16INK4a mutations in some melanoma prone kindred and the loss 
or somatic mutation in many melanoma cell lines, strongly 
suggest that p16INK4a is a melanoma tumor suppressor gene 
(Kamb A et al, 1994; Hussussian CJ et al, 1994).  
The genetic inactivation of the p16INK4a gene in almost all 
pancreatic cancer means that a critical regulator of the cell cycle 
is lost in pancreatic cancer. p16INK4a alterations are considered to 
be an early event in pancreatic carcinogenesis, detected even in 
PanIN-1A, but they represent a more typical finding in duct lesion 
with significant atypia.  
The function connections among Rb, p16, cyclin D1, and Cdk4 
imply that abrogation of the Rb/p16 pathway through alteration of 
any of these four proteins should result in similar effects upon 
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tumor progression. Analysis of a variety of human cancers has 
revealed that only one of the four members of the Rb/p16 
pathway is inactivated in a given tumor. In pancreatic carcinoma, 
the Rb/p16 pathway appears to be almost exclusively inactivated 
by alteration of the p16 protein and, only rarely, the Rb protein 
(Schutte M et al, 1997). p16INK4a is inactivated in almost all 
PDAC:  in 40% of pancreatic cancer by homozygous deletion, in 
another 40% by an intragenic mutation in one allele of the gene 
coupled with loss of the second allele, and in 15% by silencing 
associated with hypermetylation of the gene’s promoter (Caldas 
C et al, 1994; Attri J et al, 2005; Maitra et al, 2006). Although 
p16INK4a alterations have been described in the majority of 
pancreatic ductal adenocarcinoma cancer cell lines, inactivation 
of this tumor suppressor gene occurs more frequently in tumor-
derived cell lines than in primary pancreatic ductal carcinoma. A 
possible explanation may lay in the marked desmoplastic 
reaction characteristic of PDAC: contaminating normal cells may 
in fact  led to an  underestimated frequency of p16INK4a  alteration 
in tumor samples (Huang L et al, 1996). 
Recent studies indicate that p16INK4a alterations may be 
associated with pancreatic cancer prognosis. For the most part, 
studies examining loss of p16INK4a expression have found an 
association with decreased survival, increased tumor size and 
increased risk of metastasis. In the study of Ohtsubo et al, 
(Ohtsubo K et al, 2003) was investigated p16INK4a expression in 
60 pancreatic carcinoma cases by immunohistochemistry. 
Pancreatic tumors were found to be larger and the survival period 
significantly shorter for patients with p16INK4a mutations, 
suggesting that p16INK4a alterations may participate in the 
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aggressiveness of pancreatic carcinoma. Similarly, two other 
studies  (Hu YX et al, 1997; Gerdes B et al, 2002) reported that 
the survival period was shorter and metastasis was more likely in 
those patients that do not showed p16INK4a expression.  
  
 
TP53 
 The p53 gene was the first tumor suppressor gene to be 
discovered in 1979. It is located on the short arm of chromosome 
17 (17p13) and encode a 393 amino acid polypeptide of 53 kDa 
(p53) . p53 is a nuclear homotetrameric transcription factor   that 
regulates the expression of genes controlling  DNA repair, cell 
cycle progression, cellular senescence, induction of apoptosis,  
and other functions involved in cellular responses to stress or 
damage (Fig.14). For its ability to integrate many signals that 
control life and death, TP53 is known as the “Guardian of the 
Genome” (Levine AJ et al, 1997).  
 
 
Fig.14 TP53 Network (from Hofseth LJ, 2004). 
 
  The p53 protein can be  divided structurally an functionally 
in several domains (Fig.15).  
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The amino-terminus part (1-44) contains the transactivation 
domain, which is responsible for activating downstream target 
genes. 
 A proline-rich domain (58-101) mediates p53 response to DNA 
damage through apoptosis.  
The DNA-binding domain (102-292) is a core domain which 
consists of a variety of structural motifs. It is the target of 90% of 
p53 mutations found in human cancers as a single mutation 
within this domain can cause a major conformational change.  
The oligomerization domain (325-356) consists of a β-strand, 
which interacts with another p53 monomer to form a dimer, 
followed by an α-helix which mediates the dimerization of two 
p53 dimers to form a tetramer.  
In the C-terminus are localized three putative nuclear localization 
signals (NLS) have been identified in, through sequence 
similarity and mutagenesis. The most N-terminal NLS (NLSI), 
which consists of 3 consecutive Lysine residues to a basic core, 
is the most active and conserved domain. Two putative nuclear 
export signals (NES) have been identified.  
The leucine-rich C-terminal NES, found within the oligomerization 
domain, is highly conserved and it has been suggested that 
oligomerization can result in masking of the NES, resulting in p53 
nuclear retention (Arrowsmith Ch , 1999). 
 
 
Fig.15 p53 structure. 
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  Normally, in a cell, the p53 protein is kept at low 
concentration by its relatively short half-time (about 20 min) 
attributable to the action of the Mdm2 oncoprotein. Mdm2 display 
a very peculiar relationship with p53. On one hand, the Mdm2 
protein binds to p53 and acts as its major cellular antagonist. 
Mdm2 has two activities which likely mediate its effect on p53 
stability. The first is Mdm2’s E3 ubiquitin ligase activity, which 
results in direct ubiquitination of p53. Once ubiquitinated, p53 is 
targeted for proteosoma-mediated degradation. The second 
manner in which Mdm2 may regulate p53 stability is through a 
potential role in regulating nuclear export of p53, thereby 
permitting degradation to occur (Fisher DE, 2001). Importantly, 
Mdm2 also serves as  a major transcriptional target gene for p53, 
thus p53 directly activates expression of it’s own negative 
regulator, producing a potent negative feedback regulatory loop 
(Levine AJ et al, 1997) (Fig.16). As long as the loop is fully 
closed, the balance between p53 and Mdm2 seems to in favour 
of the latter, resulting in continuous repressing of p53 activity and 
its maintenance in a biological inert state (Ore M et al 2002).  
 
 
Fig.16 p53 regulation by Mdm2 (from Oren M, 2002). 
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  The p53, normally “off”,  is activated only when cells are 
stressed or damaged. Such cells poses a threat to the organism: 
they are more likely than undamaged cells to contain mutations 
and exhibit abnormal cell-cycle control, and present a greater risk 
of becoming cancerous. The p53 protein shuts down the 
multiplication of stressed cells, inhibiting progress the cell-cycle. 
In many cases it even causes the programmed death (apoptosis) 
of cells in an attempt to contain the damage and protect the 
organism (Vogelstein B et al, 2000). In response to stresses the 
activation of p53 as a transcription factor involve firstly its 
stabilization. Upon cellular stresses, p53 protein is in fact 
accumulated in the cells as a consequence of a lowering of the 
rate at which p53 is degraded. The most known stress able to 
active p53 is DNA damage (Fig.17). DNA break, such as that 
produced by γ-irradiation, is sensed by ‘checkproteins’ that retard 
progress through the cell cycle until the damage is mended. The 
main kinase in question is called AMT (ataxia telangiectasia 
mutated). Phosphorylation of p53 by ATM at amino-terminal sites 
near the Mdm2-binding region block p53 interaction with Mdm2, 
leading to stabilization of p53. Moreover Mdm2 is a rapid, DNA 
damage/ATM-dependent target for phosphorylation, thus 
becoming impaired in its ability to promote p53 degradation 
(Anderson CW and Appella E , 2002) .     
Another pathway is triggered by aberrant growth signals, such as 
those resulting from oncogenes activation. Oncogenes such as 
RAS or c-MYC when activated or overexpressed, stabilize p53, 
and dependent on the cell type, induce senescence (RAS) or 
apoptosis (c-MYC) through signalling pathways that activates 
Introduction 
  39
ARF, the product of the alternative reading frame of the cell-cycle 
regulatory gene INK4a/CDKN2a. Specifically, AFR binds to 
Mdm2 sequestering Mdm2 into the nucleolus away from p53. 
Thus, the oncogenic pathway neutralizes Mdm2 function and 
physical removal of Mdm2 rather than by modifying the substrate, 
p53 (Moll Um et al, 2003).  
Tumor hypoxia occurring in most solid tumors, induce p53 
stabilization as a result of the down regulation of Mdm2 with 
concomitant phosphorylation of p53.  
In addition  to DNA damage, hypoxia is able to activate p53 
protein.  
 
 
Fig.17. Regulatory processes in the  p53 network (from Moll UM, 
2003). 
 
P53 accumulation alone is not sufficient to fully activate p53-
dependent transcription. Studies by Hupp at al indicated that p53 
is synthesized in a latent from that is incompetent for sequence-
specifying DNA binding because the C-terminus of p53 normally 
fold back and negatively regulate the sequence-specific DNA-
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binding domain of the protein. As a consequence of cellular 
stresses, acetylation or phosphorylation of residues near the C-
terminus of p53 cause conformational changes in the protein, 
leading to the binding of p53 with the DNA.  
The increased concentration and the subsequent activation of 
p53 allows the protein to carry out its major function: to bind to 
particular DNA sequences and activate the expression 
(transcription) of adjacent genes. The downstream events 
mediated by p53 take place by two major pathways: cell cycle 
arrest and apoptosis. One of the first effects of p53 expression, in 
nearly all mammalian cell type, is a block in the cell-division 
cycle. The p53 protein directly stimulates the expression of 
p21WAF1/CIP1, an inhibitor of expression of cyclin-dependent kinase 
(CDKs). Through its negative effects on various CDKs, 
p21WAF1/CIP1 inhibits both the G1-to-S and G2-to mitosis 
transitions. In epithelial cells p53 also stimulates the expression 
of 14-3-3σ, which sequesters cyclin B1-CDK1 complexes outside 
the nucleus and thereby helps to maintain a G2 block (Fig.18).  
Some cells in which p53 is activated undergo programmed cell 
death. There are several potential mediators of p53-induced 
apoptosis. The Bax protein is an apoptosis-inducing member of 
the Bcl-2 protein family. Transcription of the Bax gene in some 
human cells is directly activated by p53-binding sites in the 
regulatory region of the gene. More recently, the NOXA and 
P53AIP1 genes have been discovered to be directly activated by 
p53. Like Bax, NOXA and P53AIP1proteins are located in 
mitochondria. When overexpressed, these proteins induce 
apoptosis (Vogelstein B et al, 2000).  
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Fig.18.  p53 pathways. 
 
  Analysis of many tumors has shown that TP53 is mutated 
in about half of all cancers, resulting in loss of apoptotic function. 
From the data available it would seem that 95% of mutations 
occur in the central region of TP53, which is responsible for 
sequence-specific DNA binding (amino acids 100-300). Tumor-
associated mutations in TP53 are predominant point mutations 
(93,%) that result in single amino acid substitutions (Redston MS 
et al, 1994). Furthermore, certain TP53 codons show an 
unexpectedly high mutation frequency, with 28% of the mutations 
affecting only six residues -175, 245, 248, 249, 273 and 282- of 
p53. The result of the mutational inactivation of TP53 by single-
amino acid substitutions is that many tumor cells retain the ability 
to express the mutant p53 protein (Fig.19). These proteins are 
often more stable than wilde-type p53, and are present at high 
levels in the tumor cells (Vousden KH et al, cer 2002). As a 
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result, the accumulation of p53 protein reaches concentrations 
detectable by immunohistochemistry.  
 
 
Fig.19.  Loss of p53 activity. 
 
One explanation for the selection of such mutations is that the 
mutant p53 proteins can act as dominant-negative inhibitors of 
the wild-type p53, which function as a tetramer. P53 protein 
contain oligomerization domains and form homotetramers, and 
this association is likely to be necessary for efficient 
transcriptional activity. Point mutations in the DNA-binding 
domain not only inactivate the mutant protein but also, as a 
consequence of oligomerization between mutant and wild-type 
protein, can lead to the inactivation of wilde-type p53 expressed 
from an unaffected allele (Lohrum M et al 2000).  The 
observation that many tumors that harbour TP53 point mutations 
also show loss of heterozygosity – effectively eliminating the wild-
type allele- indicates that the efficiency of dominant-negative 
inhibition might not be complete.  
  The TP53 is inactivated in 55-75% of PDAC, almost 
always by an intragenic mutation in one allele coupled with loss 
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of the second allele (Maitra et al, 2006). P53 mutation appears in 
later-stage PanINs that have acquired significant feature of 
dysplasia. In these more advanced PanINs, the selective 
pressure to eliminate TP53 may stem in part from a collective 
accumulation of  genetic damage, from telomere erosion and 
ROS, for example, resulting in the activation of p53-dependent 
DNA damage checkpoint responses (Hezel AF et al, 2006). 
Thus, TP53 loss probably facilities the rampant genetic instability 
that characterize this malignancy and provide a basis for its 
resistance to therapeutic modalities (Chen M et al, 2000; 
Galmarini CM et al, 2002). Given that human PDAC is 
characterized by profound aneuploidy and complex chromosomal 
rearrangements, as well as great intratumoral genomic 
heterogeneity, a clear understanding of how p53 participates in 
genomic stability would provide insight into PDAC pathogenesis.  
A recent study (Onizuka S et al, 2004) suggests that evasion of 
apoptosis may play an important role in  PDAC. In particular the 
authors report that p53- positive immunohistochemical staining, 
combined with Bcl-2-negative staining in pancreatic cancer was 
related to both histologic and clinical staging, and that the 
expression of wild-type p53 in Panc-1 cells induced apoptosis . 
Recent research has revealed that apoptosis and angiogenesis 
are closely interrelated. Wild-type p53 was found to inhibit 
angiogenesis in fibroblast through regulation of the synthesise of 
thrombpspondin-1 a potent antiangiogenic protein . Thus, these 
observations suggest that inactivation of p53 in PDAC may be 
associated with apoptosis and also angiogenesis. However, p53 
mutations have surprisingly been associated with increasing 
chemosensitivity. It has been postulated that p53 inactivation, 
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through mutation, may render tumor cells more sensitive to 
certain anti.cancer drugs, such as cisplatin, due to loss of ability 
to repair drug-induced DNA damage.  In light of the presente 
evidences, p53 mutations alone are unlikely offer useful 
prognostic information in patient with pancreatic cancer. 
 
 
SMAD4 
SMAD4, also known as DPC4 ( deleted in pancreatic cancer) 
was originally isolated from the human chromosome 18q21 
(Hahn SA et al, 1996). SMAD4 is a member of the SMAD family 
and regulates transduction of the TGFβ super family. TGFβ 
signalling pathway involves membrane receptors and SMAD 
transcriptional factors. TGFβ is a member of a family of dimeric 
polypeptide growth factors and virtually every cell in the body, 
including epithelial, endothelial, haematopoietic, neural, and 
connective-tissue cells, produce TGFβ. There are three isoforms 
of TGFβ: TGFβ1, TGFβ2, and TGFβ3. Each form is encoded by 
a distinct gene and its expressed in a tissue-specific and a 
developmentally regulated fashion, with   TGFβ1 the most 
abundant and universally expressed among the three isoform. 
TGFβ is secreted in the extracellular matrix as a latent protein, 
and the mechanism of its activation, which is required for 
biological function, occurs through poorly understood 
mechanisms (Blobe GC et al, 2000). One activated TGFβ 
regulates cellular processes by binding to three high affinity cell 
surface receptors known as type I (TβRI), II (TβRII), and III 
(TβRIII). TβRIII are the most abundant type and they function as 
non-signal receptors  as they  function only by binding TGFβ. The 
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TβRI and TβRII type  are instead serine/threonine kinase 
signalling receptor, being able to transduce the TGFβ  signal 
inside the cell (Fig.20).  
In brief, the TGFβ ligand either binds to TβRIII, which present 
TGFβ to TβRII, or binds to TβRII directly. Once bound to TGFβ, 
TβRII recruits, binds, and transphosphorylates TβRI, thereby 
stimulating its protein kinase activity. The activated TβRI 
specifically recognizes and phosphorylates a family of 
transcription factors, the SMADs. SMAD2 and SMAD3 are 
receptor-activeted  proteins, because they are phosphorylated by  
TβRI. Phosphorylated SMAD2 or SMAD3 then can associate with 
SMAD4- a share partner of all receptor-activated SMADs that is 
not phosphorylated in response to TGFβ but is essential for the 
formation of the SMAD transcriptional complex. The resulting 
SMAD complex then moves to the nucleus, where interacts in a 
cell-specific manner with transcription factors to regulate the 
transcription of a multitude of TGFβ-responsive genes (Elliott RL 
and Blobe GC, 2005). SMAD6 and SMAD7 are instead inhibitory 
SMADs that block the phosphorylation of SMAD2 or SMAD3, 
thus inhibiting TGFβ signalling.  
Although TβRs and SMADs are the core of TGFβ signalling 
pathway, SMAD-independent signalling has also been reported. 
These alternative pathway comprise mitogen-activated protein 
kinase (MAPK) signalling pathway, Rho guanosine 
triphosphatases, PI3Kinase/Akt; precise molecular mechanisms 
by which the TGFβ signalling pathway signals to these pathway 
have not been established (Elliott RL and Blobe GC, 2005).  
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FIG.20.  Mechanism of Signalling  Transduction Mediated by  TGFβ 
(from Blobe GC, 2000). 
 
 In normal cells TGFβ pathway control many fundamental 
aspect of cell behaviour, and TGFβ acts as a tumor suppressor 
by inhibiting cellular ptoliferation or by promoting cellular 
differentiation or apoptosis. 
 In human cancer TGFβ pathway  has a complex role, 
being involved in the hallmark events that occur in virtually all 
cancers. Among these hallmarks are  the ability of tumor cells to 
proliferate in the absence of exogenous growth factors, invade 
e metastasize, recruit a blood supply through angiogenesis, and  
evade apoptosis (Fig.21). 
 TGFβ is an important regulator of cellular proliferation. In  
normal cells it potently inhibits epithelial, endothelial, and 
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hematopoietic cell proliferation, preventing the cell progression 
through the cell cycle first by induction of cell cycle regulators 
such as p15INK4B and p21CIP1, and second by directly 
suppressing c-MYC expression. In cancer cells, mutations in 
the TGFβ pathway have been described that confer resistant to 
growth inhibition by TGFβ, thus allowing uncontrolled 
proliferation of the cells.   
 TGFβ normally stimulates the production of the 
extrcellular matrix by increasing the production of the 
extracellular proteins, decreasing the production of enzymes 
that degrade the extrcellular matrix. However, during 
tumorigenesis, TGFβ frequently stimulates the proteolytic 
activity of cancer cell, leading to a decreased cell  
adhesiveness and increased cell invasive capability. 
 TGFβ is a cytokine that regulates angiogenesis, and can 
function either as a proangiogenic or antiangiogenic factor in 
vitro. Recent evidences support a TGFβ proangiogenic role in 
vivo: mice with deletion of TGFβI or TGFβII receptors result to 
have a decreased and defective vasculogenesis. Stimulation of 
angiogenesis may be another mechanism by which TGFβ 
stimulates the growth of late-stage tumors.  
 The mechanism by which TGFβ induces and regulates 
apoptosis are cell and context specific, but in most cases the 
TGFβ signalling is proapoptotic and frequently activated by the 
SMADs-dependent pathway. TGFβ-induced apoptosis may 
occur through both p53-dependent and p53-independent 
mechanisms, and involves caspase activation, upregulation of 
proapoptotic factors( i.e., Bax), and /or downregulation of 
antiapoptotic factors (i.e., Bcl-2 and Bcl-xL). Resistant to TGFβ-
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induced apoptosis is an essential component particularly for 
cancer arising from tissue in which TGFβ is a prominent 
regulator of apoptosis, such as prostate cancer.   
 
 
FIG. 21.  Role of   TGFβ in Cancer (from Blobe GC, 2000). 
 
 The role of the TGFβ pathway in human tumor 
progression  is complex, TGFβ exerting both growth-inhibitory 
and growth promoting effects depending on the cell type and 
cell context. The precise mechanism for the dichotomous 
function of TGFβ in human cancer remains elusive. In one 
proposed model TGFβ function as a tumor suppressor on 
precancerous epithelial cells. During tumor progression the 
epithelial-derived cancer cells become resistant to the tumor 
suppressor effect of TGFβ, then increase the production of 
TGFβ  which now acts as tumor promoter predominantly 
through effect on the stroma compartment (Fig.22).  
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Another scenario proposes that TGFβ acts only on tumor cells: 
TGFβ switch from tumor suppressor to tumor promoter when 
epithelial-derived cancer cells undergo an EMT. Tumor cells 
that have lost cytostatic response but retained TGFβ signalling 
component can undergo EMT in response to TGFβ, becoming 
more invasive (Siegel PM and Massague J, 2003).  
 
 
FIG. 22.  Role of   TGFβ in Cancer as a Tumor Suppressor and 
Tumor Promoter (from Elliott RL 2005). 
 
 Given the antiproliferative and apoptotic functions of 
TGFβ in normal tissue , it is not surprising that TGFβ pathway is 
disrupted by mutation in human cancers. 
Mutations in TβRII are frequently observed in colon cancers 
that posses microsatellite instability (MSI), but are also found in 
15% of microsatellite stable colon cancers. These mutations 
arise within a region that encodes the TβRII extracellular 
domain, and result in a truncated and inactivated form of the 
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receptor. These kind of mutations can also be found in MSI 
gastric tumors and gliomas, but are infrequent in MSI cancer of 
the endometrium, liver and breast (Siegel PM and Massague J, 
2003). Mutation targeting TβRI have been observed in ovarian, 
breast, and pancreatic cancer (Goggins M et al, Cancer 
Research 1998). 
 Mutation resulting in loss of function or decreased 
production of the TGFβ signalling molecules SMAD2 and 
SMAD4 have been also identified in human cancers.  
Although infrequent, SMAD2 mutations are found in human 
colorectal and lung cancers.  
SMAD4 was first identified as a tumor-suppressor gene 
(originally named deleted in pancreatic carcinoma locus 4, 
DPC4). SMAD4 mutations have been identified in near 10% of 
all colon cancers and 30% of metastatic colon cancers, with 
lower frequencies in other cancer types.  
 The importance of  TGFβ signalling in PDAC is illustrated 
by the fact that SMAD4 genetic inactivations appear to be 
specific for pancreatic cancer, being rarely observed in other 
tumor types. 90% of pancreatic tumors show loss of 
heterozygosity (LOH) at the SMAD4 locus, with 55% of PDAC 
having either homozygous deletion (35%)  or mutational 
inactivation of the second allele (20%). All SMAD4 mutants are 
affected in their nuclear localization through impaired 
heterodimerization with other SMAD proteins, resulting unable 
to mediate gene transcription. Loss of SMAD4 expression 
occurs biologically late in the pancreatic neoplastic progression, 
at the stage of histologically recognizable carcinoma (Wilentz 
RE et al, 2000). The exact relationship between  SMAD4 and 
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prognosis in PDAC has not yet been elucidate. Despite one 
report, which found that loss of SMAD4 expression resulted in 
significantly shorter survival following resection, other studies 
have failed to corroborate this. One possible explanation for this 
discrepant result is that immunohistochemical analysis may not 
differentiate between wild-type and mutate SMAD4 proteins 
(Garcea G et al, 2005).  
The dichotomous function of TGFβ, TGFβ exerting both growth-
inhibitory and growth promoting effects, has been elegantly 
confirmed in PDAC by Bardeesy and colleagues (Bardeesy N et 
al, 2006). Using genetically engineered mice, the authors 
determined the role of SMAD4 deficiency on the 
initiation/progression of PDAC in combination with activated 
KRAS(G12D) allele. Results from this study provide genetic 
confirmation that SMAD4 is a PDAC tumor suppressor, 
functioning to block the progression of KRAS(G12D)-initiated 
neoplasms, whereas in a subset of advanced tumors, intact 
SMAD4 facilitates epithelial-to mesenchimal transition (EMT) 
and TGFβ-dependent growth. 
In vitro experiment of restoration of SMAD4 in SMAD4 deleted 
pancreatic cancer cells showed the abolition of tumorigenesis in 
immunodeficient mice due to suppression of angiogenesis. This 
evidence suggest that loss of SMAD4 in PDAC may have a 
primary role in modulating the interaction between epithelial 
cells  and stromal cells rather than in growth control of the 
tumor cells themselves (Schwarte-Waldhoff I et al, 2000).   
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Origin of Pancreatic Cancer 
 
At the histological level PDAC resembles pancreatic duct cells 
displaying cuboidal shape, ductal antigen expression, and 
growth in tubular structures. This means that the pancreas 
changes from acinar cell-predominant tissue to a tissue 
comprised predominantly of ductal epithelium. Consistent with 
this observation is the widely held view that this malignancy 
arises from normal ductal cells.  Nevertheless, recent studies 
pointing to the enormous plasticity of each type of pancreatic 
cell in changing their phenotype from one type to another (i.e. 
transdifferentiation), makes the identification of tumor cell origin 
more complex. Thus it is largely unknown whether PDAC arises 
from duct cells , islet cells, or another cell type in the pancreas.  
 The ductal structure of the PDAC and the ability of the 
ductal cells to proliferate are the reasons to suggest that ductal 
cells are the origin of PDAC. Evidence for the derivation of 
pancreatic tumors from ductal cells is derived mostly from 
pathomorphological studies. The presence of much greater 
incidence of ductal hyperplasia in patients with pancreatic 
cancer rather than in patients without cancer, give rise the 
hypothesis that such lesions might represent incipient 
pancreatic adenocarcinoma, indicating ductal cells as the 
precursor of cancer cells. The expression of ductal markers in 
cancer cells went along with this possibility. Studies of Pour et 
colleagues (Pour PM et al, 2003) point out evidence for the 
derivation of pancreatic tumor from β-islet cells, which were 
thought to represent facultative precursor cells. In vivo studies 
of carcinogenetic effect of N-nitrosobis(2-oxopropyl)amine 
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(BOP) on hamster pancreas revealed the presence of 
intrainsular lesions with histological appearance of ductular 
structures showing different stages of progression from normal 
to malignant pattern. Moreover, ductal adenocarcinoma derived 
from islet cells showed mutations of the KRAS and inactivation 
of the p16 genes. Intrainsular ducal formation and their 
malignant counterparts have also been observed in the human 
pancreas. About 70% of pancreatic cancer patients with an 
altered glucose tolerance harbour islet cells expressing ductal 
cell markers and develop intrainsular ductal structures that 
express the same antigens. Unfortunately all these evidences  
provide only limited information about the normal cell types from 
which pancreatic cancer arises, and the true “cell-of-origin” is 
still unknown. In fact the arguments about the expression of 
ductal markers and the genetic abnormalities are unsupported, 
normal ductal cells or islet cells giving rise to pancreatic cancer 
harbouring both these features.  
 One particularly attractive model suggest that tumors 
might arise from stem cells embedded in adult tissues. Recent 
findings have been given increasing evidence that tumors might 
also contain cancer stem cells, rare cells with indefinite 
proliferative potential that account for the growth of tumors and 
which might be resistant to conventional therapy. An adult stem 
cell of a given organ posses both the ability to both self-renew 
and differentiate into the cellular components of the organ. 
These unique properties are tight regulated in normal 
organogenesis, and the de-regulation of self- renewal might be 
one of the key events involved in carcinogenesis (Zhang M and 
Rosen JM, 2006). Evidence for the existence of cancer stem 
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cells, a limited population of tumor cells also capable of self-
renewal and responsible for giving rise to all component of a 
heterogeneous tumor, was first demonstrated in acute 
myelogenous leukemia (AML) (Marx J, Science 2003). In the 
early 1990s Dick and his colleagues (Bonnet D, Dick JE, 1997) 
suggested that the rare leukemia-initiating cells were cancer 
stem cells originated from the transformed normal stem cells . 
By contras, studies by Weissman and colleague (Cozzio A et al, 
2003) suggested that also the committed short-lived myeloid 
progenitors can be transformed and give rise to tumors with 
comparable latencies and gene expression profile. All these 
results support the hypothesis that the cell of origin of cancer 
stem cells might be normal stem and /or more committed 
progenitor cell populations as a consequence of  activation of 
specific oncogenes and /or loss of specific tumor suppressor 
genes or epigenetic events. Researchers in solid tumors, such 
as lung, brain, breast, and prostate have now xxx to identify 
stem and/or progenitor cells that can initiate tumorigenesis  
(Marx J, 2003). Surprisingly, ‘side populations’ of cells with stem 
cell characteristics have been isolated from several cell lines 
derived from a range of tumors (Mackenzie IC, 2006). 
Proportion of stem cells in a tumor may determine how deadly it 
is - a finding that could have prognostic implications. Recent 
studies, in fact, support the hypothesis that stem and/or 
progenitor cells may be responsible for drug resistance, 
metastasis and cancer recurrence.  Cancer stem cells are 
relatively quiescent cells, therefore avoiding the toxicity of the 
anticancer drugs that target the rapidly dividing cells. Moreover 
members such ATP-binding cassette transporters are highly 
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expressed in cancer stem cell, conferring  these cells a self-
defence  system against xenobiotics. Thus, all these findings 
highlight the possibility that the putative cancer stem cells might 
be responsible for the resistance to chemotherapy observed in 
several tumors (Zhang M and Rosen JM, 2006).  Comparison of 
genes involved in normal stem cell self-renewal with those 
involved in metastasis in a mouse model of prostate cancer  
revealed, an 11-gene signature. Among these genes Wnt, Hh, 
Notch and Bmi1 genes have been thought to represent a 
signature for cancer metastasis and recurrence.  
One strategy to identity the cellular of origin of PDAC is to focus 
on stem cells in the adult pancreas. It is currently unknown 
whether PDAC also harbour cancer stem cells, but since most 
cancer therapies failed to threat pancreatic tumor, and since 
cancer stem cells may more resistant to chemotherapy, the 
question is not merely an academy one. A recent study on the 
role of oncogenic RAS mutations in pancreatic tumorigenesis 
on a mouse pancreatic model (Hingorani SH et al, 2003) favour 
an alternative scheme for the development of PanINs pointing 
out their stem origin. The authors proposed that pancreatic 
stem cells periodically undergo either cell division or enter into a 
differentiation pathway. The periodic diversion of a progenitor 
cell that express the mutation in KRAS (KRASG12D) toward 
differentiation along a ductal pathway provides the basis for the 
evolution of a PanIN. Cellular injury, such as those associated 
in acute a chronic pancreatitis, stimulates increased entry of 
progenitor cells into the differentiation pathway and increase 
number of PanIN.  However, pancreatic stem cells have not yet 
been isolated despite extensive efforts.  
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Recent observations have highlight a more dynamic view of 
stem cells in which “stem-ness” represents a differentiation 
state rather than a discrete entity. It is possible that cells with 
stem cell activity may arise by “transdifferentiation” or 
“dedifferentiation” of other cell types: these “facultative” stem 
cells would be differentiated cells that have the potential to 
assume a stem cell role under particular condition of stress. In 
PDAC a “facultative” stem cell might be the pancreatic 
centroacinar cells (CAC).  
First evidence of CAC involvement in PDAC came from a study 
performed by Pour in 1980s (Pour PM, 1988).  The author 
demonstrated that centroacinar cells were the progenitor cells 
of pancreatic tumors induced by a group of nitrosamine in the 
hamster model.  
Recent studies indicate CAC as candidates for “facultative” 
stem cells. CAC are in fact strategically located at the interface 
of the acinar structure and the ductal system, and CAC are very 
similar to duct cells, exhibiting only subtle differences in apical 
membrane features.  
Mice with a pancreas-specific deletion of the Pten gene 
exhibited a widespread metaplastic transformation of the acinar 
pancreas into duct-like structures, causing significant mortality 
in animals within their first few months of age. Animals which 
survived beyond this age developed adenocarcinoma (Stanger 
BZ et al, 2005). The model emerged from this study is in favour 
of a ductal metaplasia as result from the proliferative expansion 
of centroacinar cells. Such a “growth and replacement” model 
identify this adult CAC as a candidate stem cell for the genesis 
of pancreatic cancer. The Notch signal pathway, it is known to 
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control pancreatic cell differentiation (Apelqvist A et al, 1999) 
and maintain embryonic pancreatic progenitor cells in an 
undifferentiated state. The persistence of Notch activity in these 
proliferating CAC is an evidence in favour of this hypothesis 
(Stanger BZ and Dor Y, 2006). Notch signalling may continue to 
play a role in adult by maintaining the undifferentiated state of 
the putative pool of pancreatic stem cells. Moreover, high 
expression levels of Hes1 gene, the  Notch target gene that 
mark normal adult CAC , has been observed in PanINs and 
pancreatic cancers. Several observations hint at alternative 
possibilities, the metaplastic conversion of acinar cells to ductal 
cells being one. Data from a recent study show that pancreatic 
epithelial explants undergo spontaneous acinar-to ductal 
metaplasia in response to EGFR signalling. The change toward 
an epithelial character was seen to be associated with nestin 
expressing intermediary cells (Means AL et al, 2005). Nestin is 
a label for undifferentiated pancreatic epithelial progenitors 
because nestin is present during early pancreatic development  
in the cells of origin for differentiated exocrine cells.  Thus, the 
re-emergence of nestin expression in mature acinar cells 
suggests that fully differentiated pancreatic epithelial cells may 
act as latent or facultative precursors.  
Finally, it is also possible that there is no unique “cell of origin” 
for PDAC. It may be that specific genetic alterations, rather than 
the target cell, define the ensuring malignant phenotype. This 
hypothesis is consistent with the view that precursor activity 
may not necessarily be limited to a discrete population of 
undifferentiated, pluripotent cell, but rather might be considered 
an inducible biologic function of fully differentiated cells. The 
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highly specific mutational profiles of different types of pancreatic 
cancers suggest that this concept may be relevant to pancreatic 
carcinogenesis.  
 
 
Experimental in vivo and in vitro models 
 
Key questions remain in term of PDAC basic biology, the role of 
stroma in tumor development and progression, and biology of 
early disease state. Two  primary model systems for studying  
pancreatic adenocarcinoma have been developed: in vivo 
models, regarding the employment of animal model, and in vitro 
models, with the use of cell lines and pathological specimens. 
Each of these models has inherent advantages and 
disadvantages. Tumor cell lines harbour all the genetic 
damages that lead to transformation and perhaps metastasis, 
however it is not possible to determine the temporal order at 
which such defects have occurred. Tumor cell lines are useful 
for evaluating responses of tumors to drugs in preclinical 
studies. Tumor specimens, on the other hands, are useful to 
understand premalignant lesions and spatial arrangement of 
tumors that occur at a precise time point of the tumor 
progression; the events the precede and follow the time point at 
which the specimen was taken cannot be determined. Animal 
models offer the possibility to study both temporal and spatial 
events; however, the  biological properties of pancreatic tumors 
that are induced in many animal model systems are distinct 
from humans, and interpretation of these findings need to be 
viewed cautiously (Kern S et al., 2001). Thus, there is the need 
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to use all of this systems to better understand the temporal and 
spatial events involved in pancreatic cancerogenesis.  
 
  
In vivo models 
 
Mouse  model: xenograft  
Since their introduction into the scientific community in 1996 
(Flanagan SP, 1996) nude mice, with their ability to host cancer 
cells, have gained popularity as a model to study human tumor 
biology. They are also used to examine the effects of 
therapeutic drugs or radiation particularly in cancers difficult to 
manage, such as pancreatic cancer.  
 Implantation of tumor cells in the subcutaneous  tissue of 
nude mice have yet limited clinical value since spontaneous 
metastases in the perenchymatous organs  were rarely 
observed. Subcutaneous tumors in donor animals never 
metastasized and resembled  encapsulated benign tumors 
rather then infiltrative malignancies, even if derived from 
undifferentiated or poorly differentiated cell lines.  Orthotopic 
models, generated by direct injection of tumor cells into the 
mouse pancreas, are considered more appropriate to mimic the 
clinical situation since they allow the growth of cellular clones 
with metastatic potential. However, this technique is far from 
being reproducible being strongly operator dependent: in fact it 
frequently happens the simultaneous metastatic spread of 
cancer cells into the intraabdominal organs during the injection 
procedure. 
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The orthotopic implantation of fragments, derived from 
subcutaneous tumors in animas or directly from patient’s 
specimens, has been proposed as superior technique better 
than cell injection  technique (Hotz HG et al, 2003).  Dislocation 
of tumor fragments from implantation sites was not seen, 
nevertheless  the success rate in obtaining a metastatic disease 
in mice is about 50% a figure by far inferior to the nearly 100% 
rate of metastatic disease observed in humans. 
 
Mouse  model: genetically engineered mice (GEM) 
Genetically engineered mice (GEM) have provided an in vivo 
system to study the biological impact of oncogenic mutations in 
a wide number of malignancies (Van Dyke and Jacks, 2002).  
GEM have the potential to identify early markers of disease and 
provide better preclinical models for therapeutic initiatives. A 
wide range of mouse models of pancreatic cancer have been 
built, all closely mirroring many of the genetic and Histologic 
characteristics of the human disease. Recent histopathologic 
review of these models has led to a consensus view, creating  a 
foundation for more accurate comparison across the different 
genetically engineered mouse models and their relationship to 
the human disease (Hruban et al, 2006).  
Human PDAC show mutational activation of K-ras gene and 
inactivation of each of the Ink4a, Arf, and p53 tumor suppressor 
genes. In the Kras Ink4a/Arf engineered model, all PDAC retain 
p53 function, indicating that loss of p53 is not an obligate step 
for tumor progression in the mouse. A notable feature of these 
models is the maintenance of the wild-type Smad4 expression 
in all tumors. However these data suffer of some important 
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biological bias since the reciprocal interactions of Arf, p53, and 
Ink4a genes are different in mouse cells compare to those 
acting in human cells (Rangarajan et al, 2004).  
Widespread chromosomal instability is a well known 
characteristic of human PDAC. Origin of chromosomal 
instability in cancer include a number of defects involving the 
mitotic spindle apparatus, various cell cycle checkpoint  
pathway, telomere dysfunction, increased ROS, and DNA repair 
systems defects (Hezel AF et al, 2006). Genomic analysis, 
using both CGH-array studies and spectral karyotyping (SKY), 
have found that all of the evaluated PDAC models have shown 
evidence of a global genomic alteration, suggesting that at least 
some of the mechanisms driving genomic instability are 
operational in these mouse models.  At the same time, it is 
worth noting that the absolute number of chromosomal 
structural aberrations in the current collection of GEM appears 
less than that observed in human PDAC. In conclusion, even if 
important insights into PDAC biology have been made using 
mouse model systems, it remain to be determined whether 
there are cross-species differences in the oncogenic pathways 
leading to development  of PDAC.  
 
 
in vitro models 
Sample preparation is one of the most important step for the 
molecular biology analysis. Study of PDAC has been greatly 
hindered by technical difficulties presented by characteristic 
host desmoplastic reaction to the tumor. Contaminating non-
neoplastic cells often preclude the detection of the genetic 
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events involved in tumorigenesis. In fact, whole tissue analysis 
are hampered by the vigorous non-neoplastic desmoplastic 
stromal response of pancreatic cancer cells that limits the 
presence of cancer cells to an average of 25% of the total cells 
of the tumour (Seymour A.B, Hruban RH, Redston M., Caldas C 
et al, 1994,). Paucity of neoplastic cells within the PDAC solid 
mass as well as scarcity (5%) of ductal epithelial cells from 
normal pancreas, for the establishment of a reference control, 
lead to the employment of various approaches in order to obtain 
cell populations enriched for non-malignant or malignant 
pancreatic ductal cells. These have included fine needle 
aspiration of cancer cells (Crnogorac-Jurcevic T , 2001), with 
the drawback of the lack of a suitable similar acquisition of 
control non malignant cells, and laser capture microdissection 
(Crnogorac-Jurcevic T, 2002), that is labour-intensive, time-
consuming and low-yielding, without amplification procedures, 
even for gene expression studies. 
The establishment of pancreatic cancer cell lines has been an 
attempt to restrict the expression profile to genes expressed 
more likely to be derived from the malignant epithelial 
component of the tumour. Permanently growing cell lines can 
represent a widely used strategy to circumvent the issue of 
neoplastic purity, representing a clinically relevant in vitro 
models of PDAC (Moore PS, 2001). Moreover the 
establishment of a large bank of pancreatic cancer cell lines 
from a wide panel of human cancer specimens may reflect the 
diversity of tumor phenotypes and could provide adequate 
models for studying pancreatic cancer disease heterogeneity.  
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Recently, cancer studies have acknowledged the active roles 
that tumor stroma can play in carcinogenesis, focusing on the 
abnormal communication between the tumor cells and their 
microenvironment. The intense stromal interaction is one of 
characteristics of PDAC, but since now the mutual interaction 
between pancreatic cancer cells and orthotopic tumor-derived 
fibroblasts have not been fully clarified. In vitro models have 
been established using pancreatic cancer cell lines and 
fibroblast in order to elucidate their mutual interactions. Co-
culture experiments has been done in indirect or direct manner. 
In the former, the cultured cancer cells and fibroblasts were 
separated by a transwell chamber with micropores to facilitate 
the study of soluble factors released by cancer cells. In the 
latter, the two kind of cells were cultivated in a mix fashion to 
highlight the importance of cellular physical contact (Qian LW et 
al, 2003). However, this kind of study do not consider the role of 
the extracellular matrix in the cross-talk between cancer and 
stromal cells. More recent experimental models have been 
developed to provide the in vitro   stromal microenvironment for 
cellular interaction: collagen gel-based co-culture models 
represent valid models for cellular interaction studies (Che ZM 
et al, 2006).  
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AIM OF THE WORK 
 
In order to provide a valid alternative to fresh tumor specimens, 
we propose newly established tumor cell lines as primary 
reagents in tumor biology studies. 
We hereby describe the establishment and characterization of 
four tumor cell lines reflecting primary tumor characteristics and 
heterogeinity at both molecular and phenotipic levels.  
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MATERIALS AND METHODS 
 
 
Establishment of pancreatic cancer cell lines 
The 4 cell lines were established from tumor specimens 
surgically removed from patients with primary PDA. Small 
fragments of tumor tissue 1 millimeter in diameter were 
obtained by mincing tumor specimen with a scalpel. The 
fragments were rinsed  with sterile phosphate-buffered saline 
(PBS) containing antibiotics and then enzymatically 
disaggregated following incubation with collagenase type IV 
solution (10 ml RPMI 1640, 1% penicillin, 1% streptomycin, 1% 
L-Glutamine, 10% FCS  plus 1mg/ml of collagenase type IV)  at 
37°C in a humidified atmosphere containing 5% CO2.  After 18 
hours of incubation the pellet was collected after  centrifugation 
at 700 g for 10 minutes and resuspended  in complete medium, 
distributed into culture flask and cultivated at 37°C in a 
humidified atmosphere of 5% CO2 in air . The growth medium 
was replaced every 4-7 days and the flask were regularly 
checked for epithelial cells and fibroblast outgrowth. Cultures 
showing extensive fibroblast growth were subjected to 
differential trypsinization until epithelial tumor cells were free 
from contaminating fibroblast. 
 
 
Serial passage and storage in vitro 
The 4 cell lines were cultured as monolayer in 25-cm2 or 75-cm2 
flask , routinely passaged by trypsinization and maintained in 
 Materials and Methods 
  66
complete culture medium. Cells at different culturing passages 
were stored in liquid nitrogen in culture medium containing 10% 
dimethyl sulfoxide and 30% FCS. 
 
 
RT-PCR Analysis 
Cells, harvested by trypsinization were subjected to RNA 
extraction using RNeasy kit (Qiagen). Four µl of total RNA 
(200ng) were used for cDNA synthesis by using reverse 
transcriptase reaction (Applera kit). Four µl of cDNA have been 
used for PCR reaction by using specific set of primers designed 
for CDKN2A and MADH4 genes; GAPDH gene was used as 
internal control. PCR products have been  examined on 2% non 
denaturing agarose gel and visualized by ethidium bromide.  
 
 
Mutational Analysis of TP53, KRAS, CDKN2A, SMAD4 and 
BRAF genes 
Mutational analysis was performed for the following exons: 
exons 4, 5, 6, 7, 8 and 9 for the TP53 gene; exon 1 and exon 2 
(codons 12, 13 and 61) for the KRAS gene; exon 1, exon 1α 
and exon 2 for the CDKN2A gene; exons 8 to 11 for the SMAD4 
and finally exons 11 and 15 for the BRAF gene. Polymerase 
chain reaction (PCR) reactions were performed in 30 µl final 
volume, containing 2 µl of DNA, 2 mM dNTP (Eurobio), 250 
ng/µl of each primer (MWG Biotech), 1.5 mM MgCl2, 1 x PCR 
Gold buffer, and 1U AmpliTaq Gold (PE Biosystems, Foster 
City, CA). PCR reactions were accomplished using a 9700 
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GenAmp PCR System (Applera). The primer sequences and 
cycling conditions are available on request. PCR products were 
purified using Millipore’s Montage PCR96 Cleanup Kit. Six µl of 
purified products were then sequenced using BigDye 
Terminator v3.1 Cycle Sequencing Kit (Applied Biosystems, 
Foster City, CA). The final sequencing reaction contained 3 µl 
of purified PCR product, 2 µl of BigDye Terminator Mix, 1.5 µl of 
primer (3 pmol), and 9 µl of BigDye Terminator v3.1 
Sequencing Buffer 5X. Thermal cycling conditions were 30 
cycles of 96°C for 10 seconds, 50°C for 5 seconds, and 60°C 
for 3 minutes. Unincorporated primers and dye terminators were 
removed using Montage-SEQ96 Sequencing Reaction Cleanup 
Kit (Millipore). Eight µl of purified samples were added to 8 µl of 
Hi-Di™ Formamide (Applied Biosystems) and denatured at 
95°C for 3 minutes. Sequencing was performed on an ABI 
PRISM 3100 Genetic Analyzer (Applied Biosystems) with 3100 
Genetic Analyzer Data Collection software, version 1.1.  
 
 
DNA-fingerprinting analysis 
The AmpFLSTR SGM Plus PCR Amplification Kit (Applied 
Biosystem) has been used in order to uniquely identify our cell 
lines with a 1 in 5 X 1012 average probability of identity and  to 
exclude any possible cross contamination among cell lines. The 
AmpFlSTR SGM Plus PCR Amplification Kit co-amplifies the 
repeat regions of the following ten short tandem repeat loci: 
D3S1358, vWA, D16S539, D2S1338, D8S1179, D2S11, 
D18S51, D19S433, TH01 and FGA. For the gender 
identification, a segment of X-Y homologous gene amelogenin 
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is also amplified, resulting in different length products from the 
X and Y chromosomes. One primer of each locus-specific 
primer pair is labeled with either the 5-FAM, JOE or NED dye, 
which is respectively detected as blue, green and yellow signals 
on the ABI Prism Genetic Analyzer 3100 instrument.  
The amount of DNA added to the each PCR reaction was 
0.125ng/µl, so 2.5 ng of DNA was added to the PCR reactions 
in a volume of 20 µl. The PCR products were analyzed in an 
automatic sequencer (ABIPrism 3100) using the GeneScan 
Analysis Software.  
 
 
Kariotype  analysis 
Cytogenetic analysis was performed on tumor cells collected by 
trypsinization. The pellet was rinsed twice in Hank’s saline 
solution, distributed in Petri dishes and incubated in Chang 
Medium at 37° in 5% CO2 for 3-4 days. After a three hours 
treatment with Colcemid solution, chromosome preparations 
were performed by conventional technique. Metaphases were 
selected and analysed by a Nikon 400 Eclipse fluorescent  
microscope and digital images were captured by Cytovision  
System  version 2.03 for Windows. 
FISH analysis was performed following conventional protocols 
on metaphases obtained by in situ tecnique using a  panel of 
painting  probes specific for each chromosome (Multi probe 
system –Octochrome: Cytocell).  
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Cytoskeleton filaments  
The expression of different class of cytokeratins as well as of 
vimentin has been investigated by immunofluorescence and by 
western blot analysis. For immunofluorescence labelling, cells 
were grown at low density on 8-wells chamber-slides (BD) for 
24 hours. After washing with PBS the cells were fixed with 4% 
paraformaldehyde for 10 minutes at room temperature and then  
permeabilized with 0,2%-0.3% of Triton X-100 in PBS.  The 
non-specific binding sites were blocked by incubation with 1% 
BSA in PBS for 45 min. at room temperature. The primary Abs 
were omitted in the negative controls. Slides were then 
incubated over night at 4°C with the following primary antibody: 
mAb (Mouse)  anti-Cytokeratin 7 (Ventana, USA) and 
mAb(Mouse) anti-Cytokeratin 18 (Novocastra Laboratories, 
United Kingdom); mAb(Mouse) anti-Cytokeratin 8 anti-
Cytokeratin 19 (DakoCytomation, Denmark); mAb (Mouse) 
anti-Vimentin (Ventana, USA) and mAb (Mouse) anti-Ezrin 
(NeoMarkers Labvision, USA)  in 0,1% BSA in PBS. After 
incubation slides were washed with PBS and further incubated 
with the Alexa fluor-488 conjugated goat anti-mouse secondary 
antibody (Molecular Probes, Invitrogen) for 2 hours at room 
temperature. After extensive washes the slides were mounted 
in ProlongGold antifade (Molecular Probes, Invitrogen) and 
observed using a confocal scanning radiance plus microscope ( 
Bio-Rad).   
 
 For Western Blot analysis cells at confluence were 
washed twice with PBS and harvested by trypsinization 
followed by centrifugation. Cells were lysed in extraction buffer 
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consisting of  8 mol/L Urea, 4% (w/v) CHAPS, 65 mmol/L DTT 
and the protein concentration was determined using a Bradford 
assay (Bio-Rad). Thirty ug of the total protein extraction of each 
sample were separated by 10% SDS-PAGE and transferred to 
nitrocellulose. The transferred membranes were probed with 
specific primary antibody and the corresponding HRP-
conjugated secondary antibody (Amersham). As internal control 
a polyclonal antibody anti β-tubulin (Santa Cruz) was used. 
Protein bands were visualised by incubating the membranes 
with enhanced chemiluminescence reagent (ECL) (Bio-Rad) 
and exposing the membranes to X-ray films.  
 
 
Assay of Ras and Ras effectors 
To examine the levels of Ras, ERK, pERK, Akt and pAkt PP78, 
PP117, PP109, and Pp161 cells were plated at a density of 
5x105 cells per 10-cm dish and grew in complete colture 
medium. After 48 hours the cells were lysed in 250µl lysis 
buffer. Samples containing 30µg protein (Ras) or 50µg protein 
(Erk, pERK, Akt, pAkt and Tubulin) were subjected to SDS-
PAGE electrophoresis, followed by immunoblotting with 1:2500 
pan-Ras Ab and 1:7500 peroxidase-goat anti mouse IgG. 
Immunoblotting with ERK (1:2000), anti pERK (1:1,000), anti 
Akt (1:1000), anti pAkt (1:2000) and anti Tubulin (1:500)Abs. 
Blots were then exposed to the appropriate secondary 
peroxidase-coupled IgGG(1:5000), and subjected to ECL. 
  
 Materials and Methods 
  71
Ras-GTP Assay 
Cells (5x105) were plated in 10-cm dishes. The cells were then 
lysed in 0.5 ml of Ras-binding domain (RBD) lysis buffer 
contaning 0.1 mM orthovanadate. Lysates containing 500µg 
protein were analyzed for Ras-GTP by the gluthatione S-
transferase (GST)-RBD pull-down assay followed by Western 
immunoblotting with pan anti-Ras Ab as described earlier (Elad-
Sfadia, 2002). 
 
 
In vitro Migration assay 
To quantify the in vitro motility of the 4 cell lines,  8µm transwell 
cell culture chambers were used. The 4 cell lines  were starved 
in medium containing 1% FCS for 1 day before the assay. A cell 
suspension (250µl; 8x104 cell/ml) in RPMI 1640 at  1% FCS 
was added to the upper chambers while 700µl of RPMI 1640  at  
5% FCS were placed in the lower wells. Thereafter the cells 
were incubated at 37°C in 5% CO2 in humidified chamber for 
12, 24, and 36 hrs. The number of cells migrated through the 
filters and seeded to the lower chamber were counted at each 
interval and then expressed as a percentage of the initial 
number of cells to provide an index of migratory activity. 
Migration experiments were done in duplicate.   
 
 
Bromodeoxyuridine  (BrdU) assay 
For the BrdU essay, the 4 cell lines in their exponentially 
growth phase,  were incubated with Bromodeoxyuridine  (BrdU) 
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10µM; 2 flasks were prepared in order to harvest the cells after 
the incubation with Bromodeoxyuridine  (BrdU) at 1 h and 3 hrs 
interval. After 1 hr of incubation, the medium of the first flask 
was removed and substituted with fresh culture medium and 
incubated for another 2 hours; while  the cells of the second 
flask were harvested, fixed in ethanol, subjected to DNA 
denaturation and stained with anti-BrdU-FITC-fluorescein-linked 
antibody. Analysis was made by FACScan (Becton Dickinson 
Immunocytometry System). After 2 hr  incubation, the treatment 
was repeated for the first flask. Cell population doubling time 
(Tpot) was calculated using the following  formula : Tpot = (Ts / 
ν)ln2 , where Ts is  time (in h) of DNA synthesis  and ν is a  
constant. 
 
 
Proliferation assays 
For proliferation assay 1x105 cells for PP78,  PP117, PP 109 
and PP161 were seeded in 6-cm tissue culture plates and 
supplemented with 2,5 ml of complete culture medium. Every 
days, for 7 days, cells of two independent plates were detached 
by trypsinisation and counted using a Neubauer hemocytometer 
chamber.      
Doubling times were determined during the exponential growth 
phase using the GraphPad Prism 3.02 software (Graphpad 
Software). 
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RESULTS 
 
 
Primary tumor samples.  
PP117 was derived from an undifferentiated adenocarcinoma 
while PP109 and  PP161 were obtained from two well 
differentiated adenocarcinoma. PP78 has been established 
from an adenosquamous carcinoma of the major pancreatic 
duct. The relevant clinicopathologic characteristics of patients 
are summarized in Table N.2.  
 
 
TABLE N.2 
 
 
 
 
In vitro Morphology 
All cell lines grow adherent to the bottom of the flask being 
characterized by a rather monomorphous population of 
epithelioid looking cells with large vesicular nuclei showing 
Cell 
line Gender Age(yr) Pathology 
In vitro 
growth 
pattern 
Pancreatic 
site Stage(TNM) 
follow-
up 
PP78 Male 68 Adenosquamous PDA 
uncohesive 
single cell Head 
III 
T4N1aM1 
 
DOD 
5 
months 
 
PP117 Male 80 PDA uncohesive single cell  Head 
III 
T3N1bMx 
DOD 
5 
months 
PP109 Female 63 PDA cohesive sheeths Head 
III 
T4N1bMx 
DOD 
20 
months 
PP161 Female 67 PDA cohesive  sheeths  Head 
III 
T3N1Mx 
DOD 
13 
months 
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several nucleoli.  PP109 and PP161 cells have a smooth cell 
boundaries and grow in large clusters. Unlikely,  PP78 and 
PP117 show an irregular cytoplasmic profile characterized by 
numerous short filipodia and ruffles growing largely as 
uncohesive single cell (Fig. 23).   
  
 
 
 
 
 
     
 
     
 
Fig.23. 4 cell lines H&E, x 40 
 
 
 
 
PP 78 PP 117 
PP 109 PP 161 
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Growth Kinetics and Doubling Time   
Doubling time was calculated in the exponential growth phase 
being  30,30 hrs for PP78, 31,60 hrs for PP117; 34,23 hrs for 
PP161 and 24,58 hrs for PP109 (Fig. 24). This data was 
confirmed by Bromodeoxyuridine  (BrdU) assay. 
 
 
 
0 24 48 72 96 120 144 168 192
2 16
2 17
2 18
2 19
2 20
2 21
2 22
2 23
PP78
PP117
PP109
PP161
Time(hr)
N
°c
el
ls
(lo
g2
)
 
Fig.24. Growth Curves of the 4 cell lines 
 
 
 
 
 
DNA fingerprinting profile 
The 4 DNA profiles are illustrated in Table N. 3.  As evidenced, 
each cell line showed an unique DNA profile that enable us to 
unequivocally identify them. These profiles were checked every 
20 passages in order to exclude any cross-contamination 
between the cell lines during passages in vitro. For privacy 
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reasons no normal matched control  was used in order to avoid 
patient’s recognition.  
 
 
 
 
TABLE N.3 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Kariotype analysis  
All cell lines analysed presented many numerical changes 
ranging from hypotriploidy (PP78 - modal number 61) to 
hypotetraploidy (PP161- modal number 89).  Chromosome 
losses were the most common abnormality mostly involving 
Locus 
Designation  
Size Range 
(bp) 
PP78 PP109 PP117 PP161 Ctrl Kit 
D3S1358 
 (114-142) 128 124 124-128-140 124-132 124-128 
vWA  
(157-209) 170 170-178 182 174 166-74 
D16S539 
 (234-274) 258 254-262 254-262 254-258 246-250 
D2S1338 
(289-341) 299 327 323-331 307-332 311-323 
Amelogenin     
 (X: 103; Y: 
109) 
103 103 103 103 103-109 
D8S1179 
(128-172) 148-170 144-152 140-144 140-144 140-144 
D21S11  
(187-243) 219 205-223 217 201-209 201-213 
D18S51  
(265-345) 291 299 287 287 283-295 
D19S433  
(106-140) 113-126 122-126 122-140 118-122 122-126 
TH01  
(165-204) 170-183-185 182 185 170-174 174-186 
FGA  
(215-353) 229-258 228-241 220 225-246 242-250 
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chromosome 18 and 21, whereas in our samples gains involved 
only chromosome 20 in cell lines PP78 and PP109.   
 Moreover a great number of structural abnormalities have 
been observed but no recurrent anomalies were present in the 
four cell lines. 
All aberrations identified were grossly unbalanced leading to the 
formation of several derivative chromosomes and of many 
abnormal chromosomes in which any specific part could be 
identified (marker chromosomes). The chromosome arms more 
frequently involved in the rearrangements were 1p, 2q, 6q, 7q, 
and 19q. 
 Fish analysis showed extra copies of some chromosomes 
(6, 7, and 20) but the intensity and size of these signals were 
significantly reduced indicating that they were partially deleted 
and revealed the presence of additional material which did not 
hybridized with the same specific chromosome painting.  These 
findings account for some apparently lost chromosome regions 
and for their role in the formation of marker chromosomes. FISH 
technique performed with painting probes, confirmed the 
pattern of chromosome aberrations revealed by the cytogenetic 
analysis and allowed us to clarify some other rearrangements. 
 
 
Line PP78 (chromosome modal number 61): 
- some derivative chromosomes  observed by conventional 
 techniques: der(1)t(1;10), der(2)t(2;3), der(7)t(7;?), 
 i(3)(p10), i(7)(p10), i(13)(q10); 
- FISH analysis showed: 
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o a derivative chromosome 7 to be originated from a 
translocation involving chromosomes 6, 7, and 18; 
o a deleted chromosome 6 was as  a derivative from a 
translocation involving chromosome 6(p) and 18(p), 
o a deleted chromosome 1 was identified as a 
derivative from a translocation (1p;20q); 
o additional material observed on the long arm of 
chromosome 17 was originated from the same 
chromosome; 
- some unidentified marker chromosomes were present (Fig. 
25). 
 
 
Line PP117 (chromosome modal number 84): 
- two different derivative chromosome 1; 
- additional material on long arms of a chromosome 2 and 
4; 
- two derivative chromosome 3; 
- deletion of long arm of a chromosome 6; 
some unidentified marker chromosomes were present (Fig. 25). 
 
 
Line PP109 (chromosome modal number 81): 
- a deletion of short arm of chromosome 3(p12); 
- a duplication of short arms of two copies of chromosome 
5 confirmed by WCP (Whole Chromosome Painting); 
- additional material of long arms of two chromosome 4: 
add(4)(q35); 
- 2 isochromosomes of the long arms of chromosome7; 
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- 2 chromosome 17 have extrachromatin attached at band 
p13. Using WCP the distal part of the additional material 
was shown to be derived from chromosome 16; 
some unidentified marker chromosomes were present (Fig. 25). 
 
 
Line PP161 (chromosome modal number 89): 
- a pericentric inversion of chromosome 1 (p12q32); 
- a deletion of chromosome 3 (p23); 
- additional material attached on short arms of 2 
chromosomes 9 in absence of the two copies of 
chromosomes 9 in a tetraploid range; 
- a deletion of short arms of both chromosomes 10 (p12) in 
the absence of the other two copies of  chromosome 10 in 
a tetraploid range; 
- additional material on the long arms of a chromosome 19; 
some unidentified marker chromosomes were present (Fig. 25). 
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Fig. 25. Karyotype of 4 cell lines cell lines 
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K-RAS, TP53,  MADH4, CDKN2A, and BRAF  analysis.  
 K-RAS: an activating mutation was found in all 4 cell lines: 
3 cell lines were mutated at codon 12. PP117 and PP161 had a 
G to A transition (GGT-GAT) whereas PP109 showed a G to T 
transversion (GGT-GTT). In PP78 cells show an activating 
mutation at codon 61 (CAA>CAC: Gln to His) of exon 2.     
 TP53: Inactivating mutations were found in all 4 cell lines: 
a polymorphism at codon 72 was also noticed in the PP109 cell 
line.  All mutations but one (PP161) were non synonymous 
mutations, while a homozygous stop codon was present in 
PP161.  
 SMAD4: given the high percentage of homozygous 
deletion (35%) of SMAD4 reported in PDC, an expression 
analysis by RT-PCR was first performed.  RT-PCR products  in 
the expected length range for SMAD4 gene was observed in all 
cell lines but PP109. In order to ascertain the integrity of the 
gene a direct sequencing analysis was then performed. The 
sequence analysis did not reveal any abnormality in coding 
sequences of SMAD4 gene in any of the expressing cell lines. 
An homozygous deletion of SMAD4 gene has been then proved 
for PP109 by the absence of any genomic sequence in the co-
amplification experiment with TP53.  
  CDKN2A: also the involvement of this gene was first 
investigated by RT-PCR.  
RT-PCR products in the expected length range were observed 
only in PP161 and PP78 cell lines. The sequence analysis 
reveal one base deletion (CCC-ACC>CCA-AC) in PP161 cell 
line within exon 1α at codon 38 giving rise to a stop codon 
(TAA) at codon 44. In PP78 cell line a one base insertion (TAC-
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GGT>TAA-CGG-T) within exon 1α at codon 44 giving rise to 
two stop codons (TGA) at codon 52 and codon 53. Co-
amplification experiments failed to amplify any genomic 
CDKN2A sequence in  PP117 and PP109 cell lines. Finally a 
loss of function of CDKN2A gene characterizes all cell lines.  
 BRAF: no mutation was found in all the examined exons.   
The oncogene and oncosuppressor genes profile is 
summarized in  Table N.4.  
 
Table N.4 
Cell 
Type K-RAS TP53 MADH4 CDKN2A BRAF 
PP 78 Mut Cod 61 CAA>CAC 
Mut Ex8: 
del Cod281-282: 
gac-cgg>gag 
w.t. 
Ex8 to 11 
Mut EX1α: 
Cod 38: del 
ccc-acc>cca-ac 
w.t. 
Ex11-15 
PP 117 Mut Cod 12: ggt>gat Mut Ex6: cod 190: cct>ctt 
w.t. 
Ex8 to 11 HD 
w.t. 
Ex11-15
PP 109 Mut Cod 12: ggt>gtt 
Mut Ex5: 
cod 172: ggt>ttt 
Pol cod 72 
HD HD w.t. Ex11-15
PP 161 Mut Cod 12: ggt>gat Mut Ex5: cod 145: tgg>tga (stop codon) 
w.t. 
Ex8 to 11 
Mut EX1α: 
Cod 44: ins 
tac-ggt>taa-cgg-t 
w.t. 
Ex11-15
 
Legend: Mut: point mutation; Wt: wild type; HD: homozygous deletion 
 
 
 
Cytoskeleton filaments pattern.  
 
Cytokeratins: CKs 7, 8, 18, and 19 were examined by 
immunofluorescence.  All 4 pancreatic cell lines show positivity 
for CKs 7, 8, 18. Cytokeratin 19 was absent only in PP78 (Fig. 
26 ). 
Vimentin: A strong signal for Vimentin was observed only in 
PP117and in PP78 cell lines. The remaining two cell lines did 
not show any reactivity (Fig. 26 ). 
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Ezrin:  Ezrin positivity was present in all cell lines. Nevertheless 
Ezrin show a distinct distribution being mainly localized at the 
plasma membrane  in PP109 and PP161 cells. Unlike in the 
former cell lines, in PP78 and PP117 cell lines Ezrin was 
localized in membrane ruffles and in short filipodia (Fig. 27 ). 
The results are summarized in Table N.5 
      
 
      TABLE N.5 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
         Fig. 26. (A)117 CK7; (B) PP78 CK7; (C) PP161 CK7; (D) PP109 
  CK7 ; (E) PP117 Vimentin; (F) PP78 Vimentin; 
Cell line CK7 CK8 CK18 CK19 Vimentin Ezrin 
PP78 + + + - + +/(filipodia) 
PP117 + 
 
+ 
 
+ + + +/ (ruffles) 
PP109 
 + + + + - +/ (membr.) 
PP161 + + + + - +/ (membr.) 
A
E
CB
F 
D
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Fig. 27. Ezrin  distribution in PP109 (g) and PP78 (h) 
 
 
In order to confirm the immunofluorescence results Vimentin, 
CK19 and Ezrin expressions were confirmed by Western Blot 
analyses. As expected Vimentin expression was limited to 
PP78 and PP117, while Ck19 expression was absent only in 
PP78. No differences were observed in the overall Ezrin 
expression (Fig. 28).   
 
 
 
 
 
 
 
 
 
Fig.28. Western blot analysis of Vimentin, CK19 and Ezrin. 
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Ras/MAPK-inase and AKT  Pathway Analysis 
Since codon 61 mutation is known to result in a more severe 
chronic activation of Ras and its down stream signals to MAPKs 
we determined the levels of active Ras and of the active ERK 
(p-ERK), active AKT (pAKT) in PP78 cells as compared with 
their levels in the remaining three cell lines, all harbored KRAS 
mutated in codon 12.  As shown in Fig.29 the levels of Ras-
GTP and of p-ERK were significantly higher in PP78 than in the 
other 3 cell lines, consistent with the known stronger impact of 
codon 61 mutation on Ras activation.   
 
 
Fig.29. Western blot analysis of Ras/MAPK, AKT  pathway. 
 
 
 
On the other hand, PP117 cell line show the highest level of 
pAKT among the 4 cell lines. This finding show the PI3K/Akt 
pathway as the most important activated pathway in PP117 
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cells, while in PP78, PP109 and PP161 cell signalling is mainly 
performed through the ERK/MAPK-inase pathway . 
 
 
Migration assay 
The divergent Ezrin distribution urged us to investigate the 
motility properties of our cell lines. The cell motility was 
determined by the time-course migration assay where the 
number of cells migrated through the filters down to the lower 
chamber was calculated as a result of two independent 
experiments. 
The index of migratory activity of the PP117 and PP78 cell lines 
(median of values being near 10%) outnumbered the index of 
the PP109 and PP161 cell lines by a hundred factor (median of 
values being near to 0,1%), revealing a clear strongest 
migratory capability for  PP117 and PP78 cell lines (Fig.30).  
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Fig.30.  Motility Assay Result
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DISCUSSION 
 
Pancreatic ductal adenocarcinoma (PDA) ranks eight in a 
worldwide ranking of cancer deaths. With respect to incidence, 
it ranks 13th and it is considered a relatively rare tumor. To date 
no effective therapy is available and tumor incidence 
approaches the mortality rate. The molecular mechanisms 
underlying this aggressiveness remain elusive. Moreover PDA 
represents a difficult tumor model to be studied in vivo. In fact, 
PDA in vivo elicits a vigorous desmoplastic reaction that lower 
the number of viable tumor cells available per single 
macroscopic field. Tissue cultures may represent a valid 
alternative representing a renewable source of tumor cells. Well 
characterized PDA cell lines might constitute an alternative 
research platform (Sipos B et al, 2003) to in vivo specimens.  
Tumor cell lines are usually recognized by karyotypic analysis 
although this approach may be extremely difficult in virtue of the  
high genetic and chromosomal instability that characterized 
PDAC. Cytogenetic analysis, performed on the 4 cell lines, 
showed an extensive chromosomal instability with a great deal 
of heterogeneity with many related clones as well as numerous 
non clonal abnormalities. Ploidy was abnormal in all the cases.  
These findings are probably due to mutations in genes involved 
in kinetochore structure and mitotic spindle formation (Karhu et 
al. 2006). Nevertheless as previously described (Johansonn et 
al. 1994, Griffin et al 1995), many chromosomes and 
chromosome regions are repeatedly present in the 
rearrangements. So,despite of the wide complexity and the 
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large number of chromosomes involved, the karyotype analysis 
did not present any specific recurrent chromosome abnormality. 
The DNA fingerprinting approach, revealing a distinct genetic 
profile in our cell lines may constitute a valid alternative 
approach to the unequivocal recognition of a given cell lines. In 
fact we could demonstrate the stability of the genetic profile  as 
obtained by CODIS also after 40 passages in vitro, in front of 
the high frequency of non-clonal abnormalities detected by 
karyotyping analysis. We hereby describe the establishment 
and the characterization of four new pancreatic cancer cell lines 
that will enrich the selection of pancreatic tumor cell lines useful 
for further studies. Three of them, namely PP117, PP109 and 
PP161, are derived from classic PDA. Histologically, the 
primary tumors were classified as well differentiated in two 
cases (PP109 and PP161) and  poorly differentiated in 
remaining case (PP117). In PDAC the amount of viable tumor 
cells is limited, because of the tumor’s conspicuous 
desmoplastic stroma, so that the establishment of new 
pancreatic cancer cell lines from tumor specimens traditionally 
has a low success rate.  Moreover, an ultrastructural study ( 
Sipos B et al, Virch Arch 2003) of a series of 12 commercial 
pancreatic cancer cell lines revealed that the vast majority 
(>80%) of them have a low grade of differentiation. This data do 
not reflect the distribution of grades among PDACs, but is 
related to the general difficulty in culturing cell lines from well 
differentiated tumors. Noteworthy, two of 4 of our cells lines, 
derived from well differentiated tumors, have retained the  
differentiated phenotype during  in vitro culture conditions.  
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PP78 cell line has been established from an  adenosquamous 
carcinoma. This tumor is a rare variant of PDA, representing 
only 2% of pancreatic cancer, being characterized by a worse 
clinical outcome than ordinary PDA. The reason for this unusual 
aggressiveness is currently unknown. Adenosquamous 
carcinomas are characterized by the coexistence of two 
different lines of differentiation, namely ductal and squamous, 
both are present in the same tumor mass. Several theories 
have been proposed to explain the biphasic appearance of this 
tumor, including a metaplastic origin of the squamous elements, 
a collision nature of the tumor and finally an origin from 
pluripotential duct cells. 
To the best of our knowledge, only three tumor cell lines, 
COLO357, KP-3 and KMP-4, cell lines, (Meitner PA et al, 1983; 
Ikeda Y et al, 1990; Kato M et al, Cancer 1999 )  derived from 
pancreatic adenosquamous carcinoma, have been 
characterized and reported in literature.  Thus, PP78  cell line 
may represent  a valid alternative to in vivo studies to 
investigate the biology of this  rare pancreatic tumor. 
PDA are characterized by known molecular abnormalities 
involving different oncogenes and oncosuppressor genes such 
as K-RAS, p16, SMAD4, and TP53. PDA shows the highest 
incidence of K-RAS mutation among human tumors, with a 
reported frequency ranging from 40 to 90% of cases. The vast 
majority of mutations (>98%) are located at codon 12, while 
codon 13 and 61 are less likely affected. Three out 4 cell lines,  
PP117, PP109 and PP161, show the characteristic K-RAS 
mutation at codon 12 according with the high frequency of this 
mutations in PDA. Unlike the aforementioned cell lines, PP78 is 
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characterized by the rare codon 61 K-RAS mutation. Curiously, 
adenosquamous carcinoma of the pancreas has been reported 
to have an in vivo frequency of codon 12 K-ras mutation lower 
then that found in classic ductal adenocarcinoma. In fact the 
adenosquamous pancreatic carcinoma  has been reported to 
bear a codon 12 K-ras mutation in only 38% of cases. No 
mutation in codon 61 has been reported to date in this type of 
tumor.  
Mutations in codon 12, 13 or 61 of the K-ras  gene result 
in an abnormal Ras gene product which is insensitive to Ras-
GTPase activating (RasGAPs) proteins (Bos, 1989 ). These 
Ras mutants remain therefore in their active GTP-bound state, 
resulting in a stronger growth-promoting signals (Scheffzek, 
1998; Basu, 1992   ).  While mutations in codon 12 or in codon 
13 reduces the RasGAP-mediated GTPase activity of ras, 
mutation in codon 61 results in ras protein with no catalytic 
activity at all. Therefore mutation at codon 61 is more efficient in 
terms of constitutive activation of ras and thus confers a 
stronger activation of the MAP kinase pathway.    
Consistently with these data, we found that the levels of active 
Ras-GTP was significantly higher in PP78 that harbour mutation 
in codon 61 than in the remaining three cell lines. Similarly, the 
levels of the active pERK recorded in PP78 were higher than 
those recorded in PP161, PP109, and PP117.  
Similarly the oncosuppressor genes TP53 and  p16 resulted 
inactivated in all cell lines either by point mutation or 
homozygous deletion as described in the overwhelming 
majority of published PDA cell lines (Sipos et al, 2003).   DPC4 
gene is inactivated in vivo in 55% of cases mostly by  
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homozygous deletion (35% of cases) or  by an intragenic 
mutation coupled with loss of the remaining allele (20%  of 
cases). In  vitro this percentage is about 36% (Moore et al, 
2001), and only the PP109 cell line lacks SMAD4 expression 
suggesting an homozygous deletion of the gene as 
documented by the lack of amplification of the SMAD4 gene in 
the co-amplification experiments.  
As the molecular signature is concerned, our cell lines are 
therefore consistent with the supposed ductal origin of their 
paired primary tumors as reported in literature. 
 All human pancreatic cancer cell lines reported until now 
have been further typified as ductal  by using a panel of 
cytoskeleton markers. In fact epithelial cell can be recognized 
and further subdivided by the expression of different molecular 
weight cytokeratins. Pancreatic tumors with a ductal phenotype 
variably express the same set of CKs as the normal duct cells 
namely CKs 7, 8, 18 and 19. All our cell lines show a strong 
reactivity for the widely represented simple cytokeratins 8 and 
18 according to their epithelial nature. These cytokeratins are in 
fact  present in simple adult as well as in early embryonic 
epithelia. Unlike these latter, CKs 7 and 19 are considered 
highly specific for the pancreatic duct terminal differentiation. 
CK19 reactivity was present in all cell lines but undetectable in  
PP 78 suggesting a lower level of differentiation in this cell line 
compared to the remaining.  
Unlike Cytokeratins, Vimentin, the major intermediated filament 
of mesenchimal cells, is generally absent from normal epithelial 
cells. Nevertheless, it is known that Vimentin expression is 
regulated during neoplastic transformation so that Vimentin 
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positivity characterizes undifferentiated carcinomas in vivo. The 
differences in the CK19 and Vimentin expression, further 
confirmed by Western Blot analysis, suggest a gradient of 
differentiation among our cell lines with PP109 and PP161 
showing the highest degree of ductal differentiation (Ck7+, 
Ck19+, Vimentin -). Moreover the co-expression of Vimentin 
and Keratins appear to identify the metastatic phenotype both in 
vivo and in vitro. These observations prompted us to verify if the 
degree of differentiation in our cell lines could parallel their in 
vitro aggressiveness. As matter of fact  in vitro migration assays 
demonstrated that PP78 and PP117 have a higher motility 
compared to the other two cell lines. This finding favours 
Vimentin expression as a result of an altered differentiation 
program better than an in vitro adaptation phenomenon.  
In order to further  explain the different in vitro migration 
characteristics of the 4 cell lines, we investigated the 
expression and subcellular distribution of Ezrin by WB and 
immunofluorescence studies respectively. Ezrin belongs to a 
family of proteins known as ERM (Ezrin-Radixin-Moesin) 
ensuring a cross-link between the actin cytoskeleton and the 
plasma membrane. They are involved in several physiological 
functions, such as in the control of cell morphology, adhesion 
and motility. Ezrin plays also an important role in terminal 
epithelial differentiation: overexpression and subcellular ezrin 
re-localization are important steps of the epithelial differentiative 
program induced by retinoic acid in  mouse F9 teratocarcinoma 
cells (Komiya et al 2005). In fact the retinoic acid (RA) induced 
epithelial differentiation is characterized by ezrin re-localization 
at cell to cell boundaries.  Moreover it has also been recently 
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demonstrated that ezrin overexpression or re-localization is 
associated with malignant progression and metastasis in many 
human tumors. Western Blot analysis reveals no significant 
differences in total ezrin expression in our cell lines while the 
immunofluorescence studies document a distinct subcellular 
localization of this protein among different cell lines. In 
particular, in PP109 and PP161 Ezrin is mainly localized just 
beneath the plasma membrane  suggesting its involvement in 
cell to cell junctions, while in PP78 and PP117, Ezrin is present  
in membrane ruffles and short filipodia, structures all involved in 
the motility machinery. This different cellular distribution well fits 
with our findings on motility assays of our cell lines as well as 
with our proposed degree of differentiation. Both Vimentin 
expression and Ezrin distribution in membrane ruffles and short 
filipodia thus appear to characterize poorly differentiated in vitro 
phenotypes.  
The role of Kras mutation in pancreatic cancerogenesis remain 
still elusive. Despite the fact this abnormality is almost 
constantly present in PDAC its relevance is debated since 
identical Kras mutations can be detected in normal, hyperplastic 
and metaplastic ductal epithelium (Luttges et al 1998). 
Moreover, the effects and the relevance of this mutation 
appears to be highly context-dependent (Guerra C et al 2003). 
Activated Kras may in fact promote either cell differentiation or 
senescence as well as enhance the proliferative activity and 
motility depending on developmental and/or differentiation state 
of the cell in which its activation occurs. In order to better 
elucidate the role of Kras mutation in our cell lines we 
investigated both the levels of Ras-GTP in each cell line 
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coupled with the phosphorylation levels of its downstream 
effector ERK. In parallel we tested also the activation of AKT 
pathway by measuring the level of p-Akt. Western Blot analysis 
for active ERK (p-ERK), and active AKT (pAKT) reveal a 
surprising diversity in the activating efficiency of the MAPKinase 
pathway among the 4 cell lines. In fact the level of Ras-GTP 
was significantly different in the four cell lines as well as the 
level of p-ERK. PP78 and PP109 resulted the most efficient cell 
lines in activating the MAP kynase pathway despite their 
different GTPase activity, while the PP117 and PP161 showed 
the lower levels.  It is interesting to note that this similar level of 
activation occur in cell lines showing different degree of 
differentiation, being PP78 the most undifferentiated (Vimentin 
+; Cytokeratin 19-). This finding further support the role context-
dependent of the biological effects exerted by a Kras mutation, 
since similar activation of p-ERK, in absence of any significative 
AKT activation and in presence of similar genetic profile (TP53 -
; p16 -) is associated to different in vitro characteristics such as 
cellular differentiation and motility.  
Nevertheless not only the degree of cellular differentiation may 
influence the fate of Kras activation but also the biochemical 
context in which it exerts its functions. In fact the simultaneous 
activation of the AKT pathway, to parity of conditions, may 
result in different in vitro aggressiveness.  
Our results confirm that PDAC is far from being an homogenous 
tumor and the same genetic profile may have profound and 
different effects on tumor biology depending on the degree of 
cellular differentiation. Our cell lines may then constitute a 
useful research platform to investigate the role of tumor 
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associated genetic abnormalities and cellular differentiation in 
order to gain new insights of  the biological characteristics  of 
this aggressive tumor . 
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